

(51) International Patent Classification:
A01N 43/00 (2006.01)

(21) International Application Number:

PCT/US2016/036972

(22) International Filing Date:

10 June 2016 (10.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/175,079

12 June 2015 (12.06.2015)

US

(71) Applicants: **BROWN UNIVERSITY** [US/US]; One Prospect Street, Providence, RI 02912 (US). **BRYANT UNIVERSITY** [US/US]; 1150 Douglas Pike, Smithfield, RI 02917 (US).(72) Inventors: **BASU, Amit**; 11 John Street, Barrington, RI 02806 (US). **REID, Christopher, W.**; 11 Secluded Court, Cumberland, RI 02864 (US). **O'CONNOR, Mary, Margaret**; 11532 165th Road, North Jupiter, FL 33478 (US). **MAGNO, Ethan, Lindsay**; 118 Grove Street, Lexington, MA 02420 (US). **JAMIESON, Mitchell, Evan**; 53469 Poinsettia Drive, Macomb, MI 48042 (US). **MILLER, Ryan, Daniel**; 21 Cider Lane, Smithfield, RI 02828 (US).(74) Agents: **LAURO, Pater, C.** et al.; Saul Ewing LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, PA 19102-2186 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL ANTIBACTERIAL COMPOUNDS AND METHODS OF MAKING AND USING SAME




Fig. 1

(57) Abstract: The invention provides novel antibacterial diamide compounds, pharmaceutical compositions comprising the compounds and methods for treating or preventing an infection in a subject using the compounds.

NOVEL ANTIBACTERIAL COMPOUNDS AND METHODS OF MAKING AND USING SAME

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to United States provisional patent application Ser. No.

5 62/175,079, filed June 12, 2015, the disclosure of which is incorporated by reference herein in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under Grant No. 2P20GM103430 awarded by National Institutes of Health. The government has certain rights in the invention.

10

BACKGROUND OF THE INVENTION

Methods for the growth -inhibition and destruction of bacteria have long been a key area of study towards the improvement of human health. Numerous antibacterial agents have been designed and manufactured, but many are now exhibiting decreased efficacy due to microbial resistance. The Centers
15 for Disease Control estimates that at least a quarter of a million illnesses and 23,000 deaths over the past year in the U.S. were due to antibiotic resistance. A report published in 2009 by the Alliance for the Prudent Use of Antibiotics (APUA) estimated that over \$20 billion dollars per year is consumed by healthcare costs to treat antibiotic-resistant infections. Although these figures could be improved by addressing the misuse and overuse of antibiotics in the clinic, an understanding of the mechanisms by
20 which bacteria develop resistance and designing drugs to circumvent these is essential for the treatment of millions of infections.

There are three general molecular mechanisms that confer antibiotic resistance. The first is the inclusion of efflux pumps into the membrane of the bacteria. These pumps prevent the accumulation of intracellular-acting antibiotics such as protein synthesis inhibitors by actively pumping them out of the
25 cytoplasm. Efflux pumps are generally adapted from existing membrane pumps used either to move lipophilic molecules in and out of the bacteria or rapidly expel naturally produced antibiotics meant to destroy neighboring bacteria. Drugs such as tetracyclines and erythromycins frequently fail to reach therapeutic concentrations due to expulsion through efflux pumps.

A second method used by bacteria is to either destroy or modify the chemically relevant features
30 of the antibiotic. This can include the cleavage of bonds within the antibiotic or chemical modification of groups on the antibiotic.

The third most method of resistance does not act on the inhibitor at all, but instead modifies the target of inhibition. By reprogramming the target structure, bacteria can reduce the efficacy of the antibiotic while retaining the inherent function of the target. Further, bacteria develop into colonies that

adhere to a surface within a dense extracellular matrix consisting of DNA, proteins, and polysaccharides, known as a biofilm. Biofilms are pervasive in implanted medical devices and damaged tissue, leading to unresolved infections.

Though plagued by numerous resistance issues, cell wall-acting antibiotics are the most prevalent inhibitors of bacterial growth, such as penicillin. In particular, potent antibiotics target the synthesis of peptidoglycan, a key component of the bacterial cell wall. Peptidoglycan resists internal turgor, mediates cell growth and division, defines the shape of the cell, and helps to anchor proteins and glycoproteins to the cell wall.

Peptidoglycan consists of the aminoglycosides N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) linked in alternating chains through β -(1-4) bonds. In *Bacillus subtilis*, each individual chain is between 50 and 250 disaccharide units. These linear glycan chains are cross-linked by short and variable peptide strands. The D-lactoyl group of MurNAc is amidated by a tetrapeptide in the mature macromolecule. Cross-linking of these peptides allows for the formation of a mesh-like matrix that surrounds the cell.

The cell wall has been a prominent target largely due to its absence in mammalian cells. Inhibitors designed for cell wall synthesis ideally only affect bacterial infections and do not damage host cells. Of the large number of cell wall synthesis inhibitors currently being developed and marketed, almost all fall into two major classes: β -lactams and macrocyclic polypeptides.

β -Lactams comprise penicillins and cephalosporins use a reactive warhead (a four-membered lactam ring) to bind irreversibly to bacterial transpeptidases involved in assembly of the cross-bridge peptide chains within the peptidoglycan. Bacteria employ enzymes called β -lactamases to destroy the warhead, opening the lactam ring and rendering the antibiotic ineffective.

Macrocyclic polypeptides include compounds like vancomycin. Vancomycin acts by tying up the peptide substrates used by transpeptidases and prevents their use as building blocks. Vancomycin's target, though, is the highly variable peptide cross-bridge that is readily modified by bacteria, thus preventing binding of vancomycin and eliminating its potential activity. Additionally, macrocyclic polypeptide drugs pose a serious problem to synthetic chemists, due to their complexity.

Presently, there are no successful antibiotics that target the natural recycling of the peptidoglycan. This hydrolytic breakdown and remodeling of the cell wall is carried out by a set of bacterial enzymes termed "autolysins" that are heavily implicated in peptidoglycan maturation, cell separation and expansion, motility, cell-wall turnover, and protein secretion. Within a single generation of bacterial growth, 50% of the peptidoglycan layer is removed and recycled by the activity of autolysins.

During vegetative growth of *Bacillus subtilis*, for example, two major enzymes present in the cell wall are involved with the autolytic activity occurring within the peptidoglycan: N-acetylmuramoyl-L-


alanine amidase (amidase) and endo- β -N-acetylglucosaminidase (GlcNAcase). These enzymes are encoded by the *LytC* and *LytD* genes respectively and are regulated by the σ^D transcription factor. Despite their substantial expression and cell-wall localization during exponential growth, neither of these enzymes is individually crucial to the survival or even proper cell-wall turnover of the cell. Furthermore, the double-knockout mutant of *LytC/LytD* had no reduction in cell separation and incomplete reduction in cell-wall turnover. The mutual compensatory nature of autolytic enzymes complicates any attempts to develop autolysin inhibitors as antibiotics.

Several compounds have some inhibitory activity against purified autolysins but all have failed to exhibit any bacteriostatic or bactericidal effect. The β -hexosaminidase inhibitor, NAG-thiazoline, was only a weak binder of LT and had no effect on the viability of *E. coli*. Analogues of 2-acetamido-2-deoxynojirimycin were not active *in vivo* even at 1 mM. Targeting autolysin enzymes that which act on the invariant glycan chain may drastically reduce the potential for development of resistance.

There is a need in the art to identify novel compounds that can be used to treat or prevent bacterial infections in a subject. Treatment with such compounds should be efficacious and prone to minimal resistance build-up, or no resistance at all. The present invention addresses and meets this need.

BRIEF SUMMARY OF THE INVENTION

The invention provides a compound of formula I, or a salt or solvate thereof:



(I), wherein in compound I:

R_1 is selected from the group consisting of aryl and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_6 alkyl, OH, $O(C_1$ - C_6 alkyl), F, Cl, Br, I, NO_2 , $-C(=O)H$, $-C(=O)OH$, $-C(=O)O(C_1$ - C_6 alkyl), $-C(=O)NH_2$, $-C(=O)NH(C_1$ - C_6 alkyl), and $-C(=O)N(C_1$ - C_6 alkyl)(C_1 - C_6 alkyl);

R_2 is selected from the group consisting of C_1 - C_8 alkyl, C_3 - C_8 cycloalkyl, allyl, propargyl, homopropargyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, wherein the alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_6 alkyl, OH, $O(C_1$ - C_6 alkyl), F, Cl, Br, I, NO_2 , $-C(=O)H$, $-C(=O)OH$, $-C(=O)O(C_1$ - C_6 alkyl), $-C(=O)NH_2$, $-C(=O)NH(C_1$ - C_6 alkyl), and $-C(=O)N(C_1$ - C_6 alkyl)(C_1 - C_6 alkyl);

R_3 is selected from the group consisting of C_3 - C_8 cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl, aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected


from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₄ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₈ cycloalkyl, arylalkyl and heteroarylalkyl, wherein the alkyl, cycloalkyl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl); and


R₅ is H or methyl.

In certain embodiments, in R₁ has at least one substituent ortho to the carbonyl group *a* selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl). In other embodiments, at least one substituent ortho to the carbonyl group *a* is selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br and I. In yet other embodiments, R₁ is selected from the group consisting of phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl and p-methoxyphenyl. In yet other embodiments, R₂ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, heteroaryl, aryl-(CH₂)₁₋₂-, and heteroaryl-(CH₂)₁₋₂-, wherein the alkyl, cycloalkyl, phenyl, heteroaryl, aryl-(CH₂)₁₋₂-, or heteroaryl-(CH₂)₁₋₂-group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, and NO₂. In yet other embodiments, R₂ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, p-methoxyphenyl, benzyl, Ph(CH₂)₂-, Ph₂CHCH₂-, and Ph(CH₃)CH-. In yet other embodiments, R₃ is selected from the group consisting of C₅-C₆ cycloalkyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, and p-methoxyphenyl. In yet other embodiments, R₄ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, benzyl, and phenyl-(CH₂)₂-, wherein the alkyl, cycloalkyl, phenyl or benzyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, and I.


In certain embodiments, the compound of the invention is selected from the group consisting of:




fgca




fgia




fgja




fgbd




fgkd




rgba




ogba




pgba




qgba




fhba




fiba




fbqb




fgka




fgna




fgqb




fgba




fgoa




fgbb




fgpa




fgkb




fgqa




fgqc




fgra




fgbc




fgla




fgta




fgkc




fgma




fgua




fgsa




fgva




fgwa




fgxa




MO2




MO3




MO4




rgkc (66%)




rgna (52%)




pgkc (48%)




rgka




rgoa




qgkc




ngkc (69%)




ogkc (72%)




fhka (65%)




fhkc (67%)




tgka (71%)




tgkc (74%)




ugkc (78%)




vgkc (53%)




faqa




faaAa




fhqa





fhaAa



fgqd



MJ02



and

The compounds of the invention have shown antibacterial activity against a variety of Gram-positive and Gram-negative bacteria including, but not limited to, *B. subtilis* Lyt, *S. pneumoniae*, *C. difficile*, and *S. aureus*.

In certain embodiments, the compound of formula I is selected from the group consisting of **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka**, **fgna**, **fgbb**, **fgqa** and **fgbc**. In one embodiment, the compound is **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** or **fgna**. These compounds have antibacterial activity against *B. subtilis* Lyt G. In another embodiment, the compound is **fgkc**, **fgbb**, or **fgbc**. These compounds have antibacterial activity against *S. pneumoniae*. In yet another embodiment, the compound is **fgba** or **fgqa**. These compounds have antibacterial activity against *S. aureus*. In another embodiment, the compound is **fgna**, which has antibacterial activity against *C. difficile*.

In certain embodiments, the salt of compound I is an acid addition salt and is selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic,

pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid, and any combinations thereof. In other embodiments, the salt is a base addition salt and is selected from the group consisting of calcium, magnesium, potassium, sodium, ammonium, zinc, a basic amine salt, and
5 any combinations thereof, wherein the basic amine is selected from the group consisting of triethylamine, diisopropylethylamine, trimethylamine, N,N'-dibenzylethylene-diamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and any combinations thereof.

The invention also provides pharmaceutical compositions comprising at least one compound of the invention and a pharmaceutically acceptable carrier. In certain embodiments, the compositions
10 further comprise at least one additional antibacterial agent. In other embodiments, the at least one additional antibacterial agent comprises at least one agent selected from the group consisting of amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and
15 zotrim. In yet other embodiments, the compound and the agent are co-formulated in the composition.

The invention further provides a method of inhibiting a N-acetylglucosaminidase in a cell comprising contacting the cell with a compound of the invention. In certain embodiments, cell is a bacterium, a fungus or a cancer cell. In yet other embodiments, the N-acetylglucosaminidase comprises an autolysin.

20 The invention also provides a method of inhibiting a N-acetylglucosaminidase in the cytosol of a cell. In certain embodiments, the method comprises contacting the N-acetylglucosaminidase with at least one compound of the invention. In other embodiments, the N-acetylglucosaminidase is derived from a bacterium, a fungus or a cancer cell. In yet other embodiments, the N-acetylglucosaminidase comprises an autolysin.

25 The invention further provides a method of treating or preventing a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, thereby treating or preventing a bacterial infection in the subject.

In yet another embodiment, the subject is further administered at least one additional antibacterial agent. In certain embodiments, the at least one additional antibacterial agent comprises at least one agent
30 selected from the group consisting of amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim. In certain embodiments, the compound of the invention and the agent are co-administered to the subject. In other embodiments, the compound of the

invention and the agent are co-formulated.

In other embodiments, the compound is administered to the subject by at least one route selected from the group consisting of intravenous, oral, inhalational, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary and topical routes. In certain embodiments, the subject is a mammal. In other embodiments, the mammal is a human.

In one embodiment of the methods of the invention described above, the bacterium is Gram-positive. In another embodiment, the Gram-positive bacterium is selected from the group consisting of *Streptococcus sp.*, *Staphylococcus sp.*, *Enterococcus sp.*, *Corynebacterium sp.*, *Listeria sp.*, *Clostridium sp.* and *Bacillus sp.* In yet another embodiment, the Gram-positive bacterium is *Clostridium difficile* (also currently known as *Peptoclostridium difficile*), *Streptococcus pneumoniae*, *Staphylococcus aureus*, vancomycin intermediate resistance *S. aureus* (VISA), *Enterococcus faecalis*, vancomycin resistant enterococci (VRE), *Streptococcus pyogenes*, *Bacillus anthracis*, *Corynebacterium diphtheria* or *Bacillus cereus*.

In one embodiment of the methods of the invention described above, the bacterium is Gram-negative. In another embodiment, the Gram-negative bacterium is selected from the group consisting of *Salmonella sp.*, *Escherichia sp.*, *Klebsiella sp.*, *Acinetobacter sp.*, *Pseudomonas sp.*, *Vibrio sp.* and *Enterobacter sp.* In yet another embodiment, the Gram-negative bacterium is *Salmonella enterica*, *Salmonella typhi*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* or *Pseudomonas aeruginosa*.

In one embodiment of the method of treating or preventing a bacterial infection in a subject described above, the compound is **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** or **fgna** and the bacteria is *B. subtilis* Lyt G. In another embodiment, the compound is **fgkc**, **fgbb**, or **fgbc** and the bacteria is *S. pneumoniae*. In yet another embodiment, the compound is **fgba** or **fgqa** and the bacteria is *S. aureus*. In still another embodiment, the compound is **fgna** and the bacteria is *C. difficile*.

In another embodiment, the methods of the invention further comprise procuring the at least one compound of the invention.

The invention further provides a prepackaged pharmaceutical composition comprising at least one compound of the invention, or a salt or solvate thereof and an instructional material for use thereof. In certain embodiments, the instructional material comprises instructions for preventing or treating a bacterial infection in a subject. In other embodiments, the prepackaged pharmaceutical composition further comprises an applicator.

Other aspects, embodiments, advantages, and features of the present invention will become apparent from the following specification.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description of various embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings certain specific embodiments. It should be understood,
 5 however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.

Fig. 1 is an illustration of the structure of peptidoglycan in a Gram-positive bacterium. See Tortora, G. J., Funke, B. R. & Case, C. L. Microbiology: An Introduction. (Benjamin Cummings, 2010).

Fig. 2 is an illustration of autolysins in *B. subtilis* and point of activity within peptidoglycan.

10 Fig. 3 is a graph illustrating fluorescence values measured over time at 250 μ M inhibitors for *B. subtilis*.

Fig. 4 is a bar graph illustrating fluorescence readings in the resazurin assay at 60 minutes (250 μ M inhibitor).

15 Fig. 5 is a bar graph illustrating fluorescence readings in the resazurin assay at 60 minutes (250 μ M inhibitor) for multiple runs (Run 1: red; Run 2: blue; Run 3: green).

Fig. 6A is an image illustrating serial dilution resazurin assay for **fgkc**, **fgka**, **fgoa**, and **rgba**. Identical experiments: Plate 1, top left, and Plate, 2 top right. Fig. 6B is an image illustrating results of a single concentration whole-cell; resazurin assay.

20 Fig. 7 is a table illustrated selected MIC values for compounds of the invention against Gram-positive pathogens.

Fig. 8 is a series of graphs illustrating the finding that **fgkc** treatment results in UDP-MurNAc-pentapeptide accumulation in *B. subtilis*. Ugi-derived terminal alkynes target peptidoglycan synthesis/metabolism. *B. subtilis* was grown to mid-exponential phase (O.D.₆₀₀ ~0.6) and all cultures treated with Chloramphenicol (Cm) (130 mg/mL) for 15 min. Cultures were then exposed to
 25 vancomycin (Van) (8 mg/mL) or **fgkc** (4x MIC) for 1 h. Nucleotide sugars were extracted with hot water and separated by C18-RP-HPLC. (*) denotes retention time of UDP-MurNAc-pentapeptide.

Fig. 9 is a graph illustrating inhibition of LytG (GH73) from *B. subtilis* by **fgka**. The assay involved *in vitro* GlcNAcase inhibition of *B. subtilis* LytG by **fgka**, as measured using turbidometric assays with purified peptidoglycan (Horsburgh, *et al.*, 2003, Biochemistry 42:257).

30 Figs. 10A-10B illustrate weak inhibition of other GH73 members by selected compounds of the invention: inhibition of FlgJ (GH73) from the Gram-negative pathogen *Salmonella enterica* by **fgba** (Fig. 10A) and **Bl.fgba** (Fig. 10B). Activity was measured as described in Herlihey, *et al.*, 2014, J. Biol Chem 289(45):31029.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any
5 methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the certain specific methods and materials are described.

As used herein, each of the following terms has the meaning associated with it in this section.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more
10 than one element.

“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of $\pm 20\%$ or $\pm 10\%$, more advantageously $\pm 5\%$, even more advantageously $\pm 1\%$, and still more advantageously $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods.

15 A disease or disorder is “alleviated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced.

In one aspect, the terms “co-administered” and “co-administration” as relating to a subject refer to administering to the subject a compound of the invention or salt thereof along with a compound that may also treat the disorders or diseases contemplated within the invention. In one embodiment, the co-
20 administered compounds are administered separately, or in any kind of combination as part of a single therapeutic approach. The co-administered compound may be formulated in any kind of combination, as mixtures of solids and liquids under a variety of solid, gel, and liquid formulations, and as a solution.

As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The
25 pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

A “disease” as used herein is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to
30 deteriorate.

A “disorder” as used herein in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.

As used herein, the term “DMSO” refers to dimethyl sulfoxide.

As used herein, the terms “effective amount,” “pharmaceutically effective amount” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

As used herein, the term “GlcNAc” refers to N-acetylglucosamine.

As used herein, the term “GNT” refers to a GlcNAc triazole.

As used herein, the term “Gram-positive bacteria” are bacteria that give a positive result in the Gram stain test. Gram-positive bacteria take up the crystal violet stain used in the test, and then appear to be purple-colored when seen through a microscope. Gram-positive bacterial include *Streptococcus sp.*, *Staphylococcus sp.*, *Enterococcus sp.*, *Corynebacterium sp.*, *Listeria sp.*, *Clostridium Sp.* and *Bacillus sp.* Examples of Gram-positive bacteria include *Clostridium difficile* (also currently known as *Peptoclostridium difficile*), *Streptococcus pneumoniae*, *Staphylococcus aureus*, vancomycin intermediate resistance *S. aureus* (VISA), *Enterococcus faecalis*, vancomycin resistant enterococci (VRE), *Streptococcus pyogenes*, *Bacillus anthracis*, *Corynebacterium diphtheria* and *Bacillus cereus*.

As used herein, the term “Gram-negative bacteria” are a group of bacteria that do not retain the crystal violet stain used in the Gram staining method of bacterial differentiation. Gram-negative bacteria include *Salmonella sp.*, *Escherichia sp.*, *Klebsiella sp.*, *Acinetobacter sp.*, *Pseudomonas sp.*, *Vibrio sp.* and *Enterobacter sp.* Examples of Gram-negative bacteria include *Salmonella enterica*, *Salmonella typhi*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa*.

“Instructional material,” as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression that can be used to communicate the usefulness of the composition and/or compound of the invention in a kit. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container that contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website.

The terms “patient,” “subject” or “individual” are used interchangeably herein, and refer to any

animal, or cells thereof whether *in vitro* or *in situ*, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject or individual is a human.

As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, *i.e.*, the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compounds prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof.

As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier is “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention

are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

The term "prevent," "preventing" or "prevention," as used herein, means avoiding or delaying the onset of symptoms associated with a disease or condition in a subject that has not developed such

5 symptoms at the time the administering of an agent or compound commences.

As used herein, the term "procure" or "procuring" as relating to a subject in need of being administered a therapeutically active compound refers to the act of synthesizing, packaging, prescribing, purchasing, providing or otherwise acquiring the compound so that the subject may be administered the compound.

10 By the term "specifically bind" or "specifically binds," as used herein, is meant that a first molecule preferentially binds to a second molecule (*e.g.*, a particular receptor or enzyme), but does not necessarily bind only to that second molecule.

A "therapeutic" treatment is a treatment administered to a subject who exhibits signs of pathology, for the purpose of diminishing or eliminating those signs.

15 As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic agent, *i.e.*, a compound of the invention (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient (*e.g.*, for diagnosis or *ex vivo* applications), who has a condition contemplated herein, a symptom of a condition contemplated herein or the potential to develop a condition contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a condition contemplated herein, the symptoms of a condition contemplated herein or the potential to develop a condition contemplated herein. Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

25 As used herein, the term "alkyl," by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (*i.e.*, C₁-C₁₀ means one to ten carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, and cyclopropylmethyl. Certain specific examples include (C₁-C₆)alkyl, such as, but not limited to, ethyl, methyl, isopropyl, isobutyl, n-pentyl, n-hexyl and cyclopropylmethyl.

30 As used herein, the term "cycloalkyl," by itself or as part of another substituent means, unless otherwise stated, a cyclic chain hydrocarbon having the number of carbon atoms designated (*i.e.*, C₃-C₆ means a cyclic group comprising a ring group consisting of three to six carbon atoms) and includes straight, branched chain or cyclic substituent groups. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Certain specific examples include

(C₃-C₆)cycloalkyl, such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

As used herein, the term “alkenyl,” employed alone or in combination with other terms, means, unless otherwise stated, a stable mono-unsaturated or poly-unsaturated straight chain or branched chain hydrocarbon group having the stated number of carbon atoms. Examples include vinyl, propenyl (or allyl), crotyl, isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and the higher homologs and isomers. A functional group representing an alkene is exemplified by -CH₂-CH=CH₂.

As used herein, the term “alkynyl,” employed alone or in combination with other terms, means, unless otherwise stated, a stable straight chain or branched chain hydrocarbon group with a triple carbon-carbon bond, having the stated number of carbon atoms. Non-limiting examples include ethynyl and propynyl, and the higher homologs and isomers. The term “propargylic” refers to a group exemplified by -CH₂-C≡CH. The term “homopropargylic” refers to a group exemplified by -CH₂CH₂-C≡CH. The term “substituted propargylic” refers to a group exemplified by -CR₂-C≡CR, wherein each occurrence of R is independently H, alkyl, substituted alkyl, alkenyl or substituted alkenyl, with the proviso that at least one R group is not hydrogen. The term “substituted homopropargylic” refers to a group exemplified by -CR₂CR₂-C≡CR, wherein each occurrence of R is independently H, alkyl, substituted alkyl, alkenyl or substituted alkenyl, with the proviso that at least one R group is not hydrogen.

As used herein, the term “substituted alkyl,” “substituted cycloalkyl,” “substituted alkenyl” or “substituted alkynyl” means alkyl, cycloalkyl, alkenyl or alkynyl, as defined above, substituted by one or more substituents selected from the group consisting of halogen, -OH, alkoxy, tetrahydro-2-H-pyran-2-yl, -NH₂, -N(CH₃)₂, (1-methyl-imidazol-2-yl), pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, -C(=O)OH, trifluoromethyl, -C≡N, -C(=O)O(C₁-C₄)alkyl, -C(=O)NH₂, -C(=O)NH(C₁-C₄)alkyl, -C(=O)N((C₁-C₄)alkyl)₂, -SO₂NH₂, -C(=NH)NH₂, and -NO₂, advantageously containing one or two substituents selected from halogen, -OH, alkoxy, -NH₂, trifluoromethyl, -N(CH₃)₂, and -C(=O)OH, more advantageously selected from halogen, alkoxy and -OH. Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2-carboxycyclopentyl and 3-chloropropyl.

As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers. In certain embodiments, alkoxy includes (C₁-C₃)alkoxy, such as, but not limited to, ethoxy and methoxy.

As used herein, the term “halo” or “halogen” alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, advantageously, fluorine, chlorine, or bromine, more advantageously, fluorine or chlorine.

As used herein, the term “heteroalkyl” by itself or in combination with another term means,

unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including

5 between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include: $-\text{O}-\text{CH}_2-\text{CH}_2-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_3$, $-\text{CH}_2-\text{S}-\text{CH}_2-\text{CH}_3$, and $-\text{CH}_2\text{CH}_2-\text{S}(=\text{O})-\text{CH}_3$. Up to two heteroatoms may be consecutive, such as, for example, $-\text{CH}_2-\text{NH}-\text{OCH}_3$, or $-\text{CH}_2-\text{CH}_2-\text{S}-\text{S}-\text{CH}_3$.

As used herein, the term “heteroalkenyl” by itself or in combination with another term means,
 10 unless otherwise stated, a stable straight or branched chain monounsaturated or poly-unsaturated hydrocarbon group consisting of the stated number of carbon atoms and one or more heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. Up to two heteroatoms may be placed consecutively. Examples include $-\text{CH}=\text{CH}-\text{O}-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{OH}$, $-\text{CH}_2-\text{CH}=\text{N}-\text{OCH}_3$, -
 15 $\text{CH}=\text{CH}-\text{N}(\text{CH}_3)-\text{CH}_3$, and $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{SH}$.

As used herein, the term “aromatic” refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, *i.e.* having $(4n+2)$ delocalized π (pi) electrons, where n is an integer.

As used herein, the term “aryl,” employed alone or in combination with other terms, means,
 20 unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings) wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl, and naphthyl. In certain embodiments, aryl includes phenyl and naphthyl, in particular, phenyl.

As used herein, the term “aryl-(C₁-C₃)alkyl” means a functional group wherein a one to three
 25 carbon alkyl chain is attached to an aryl group, *e.g.*, $-\text{CH}_2\text{CH}_2$ -phenyl or $-\text{CH}_2$ -phenyl (benzyl). Examples included aryl-CH₂- and aryl-CH(CH₃)-. The term “substituted aryl-(C₁-C₃)alkyl” means an aryl-(C₁-C₃)alkyl functional group in which the aryl group is substituted. Specific examples include substituted aryl(CH₂)-. Similarly, the term “heteroaryl-(C₁-C₃)alkyl” means a functional group wherein a one to three carbon alkylene chain is attached to a heteroaryl group, *e.g.*, $-\text{CH}_2\text{CH}_2$ -pyridyl. One embodiment is
 30 heteroaryl-(CH₂)-. The term “substituted heteroaryl-(C₁-C₃)alkyl” means a heteroaryl-(C₁-C₃)alkyl functional group in which the heteroaryl group is substituted. Specific examples include substituted heteroaryl-(CH₂)-.

As used herein, the term “heterocycle” or “heterocyclyl” or “heterocyclic” by itself or as part of another substituent means, unless otherwise stated, an unsubstituted or substituted, stable, mono- or multi-

cyclic heterocyclic ring system that consists of carbon atoms and at least one heteroatom selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or non-aromatic in nature. In one embodiment, the heterocycle is a heteroaryl.

As used herein, the term "heteroaryl" or "heteroaromatic" refers to a heterocycle having aromatic character. A polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include tetrahydroquinoline and 2,3-dihydrobenzofuryl.

Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazoline, pyrazolidine, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydropyridine, 1,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, homopiperazine, homopiperidine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin and hexamethyleneoxide.

Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl (such as, but not limited to, 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.

Examples of polycyclic heterocycles include indolyl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (such as, but not limited to, 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (such as, but not limited to, 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (such as, but not limited to, 3-, 4-, 5-, 6-, and 7-benzothienyl), benzoxazolyl, benzothiazolyl (such as, but not limited to, 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl.

The aforementioned listing of heterocyclyl and heteroaryl moieties is intended to be representative and not limiting.

As used herein, the term "substituted" means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.

For aryl, aryl-(C₁-C₃)alkyl and heterocyclyl groups, the term "substituted" as applied to the rings of these groups refers to any level of substitution, for example, mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and

substitution may be at any chemically accessible position. In one embodiment, the substituents vary in number between one and four. In another embodiment, the substituents vary in number between one and three. In yet another embodiment, the substituents vary in number between one and two. In yet another embodiment, the substituents are independently selected from the group consisting of C₁₋₆ alkyl, -OH, C₁₋₆ alkoxy, halo, amino, acetamido and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic, in particular, straight.

In this disclosure, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U.S. Patent law and can mean “includes,” “including” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

Throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.1, 5.3, 5.5, and 6. This applies regardless of the breadth of the range.

The invention is based, at least in part, on the unexpected identification of novel small molecule inhibitors of N-acetylglucosaminidases. In certain embodiments, the compounds of the invention inhibit bacterial autolysins.


In one embodiment, the compounds of the invention are active against Gram-positive bacteria. In another embodiment, the Gram-positive bacterium is selected from the group consisting of *Streptococcus* sp., *Staphylococcus* sp., *Enterococcus* sp., *Corynebacterium* sp., *Listeria* sp., *Clostridium* sp. and *Bacillus* sp. In yet another embodiment, the Gram-positive bacterium is *Clostridium difficile* (now *Peptoclostridium difficile*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, vancomycin intermediate resistance *S. aureus* (VISA), *Enterococcus faecalis*, vancomycin resistant enterococci (VRE), *Streptococcus pyogenes*, *Bacillus anthracis*, *Corynebacterium diphtheria* or *Bacillus cereus*.

In another embodiment, the compounds of the invention are active against Gram-negative bacteria. In another embodiment, the Gram-negative bacterium is selected from the group consisting of *Salmonella* sp., *Escherichia* sp., *Klebsiella* sp., *Acinetobacter* sp., *Pseudomonas* sp., *Vibrio* sp. and

Enterobacter sp. In yet another embodiment, the Gram-negative bacterium is *Salmonella enterica*, *Salmonella typhii*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* or *Pseudomonas aeruginosa*.

In one embodiment, compounds of formula I **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** and **fgna** are effective against *B. subtilis* Lyt G. In another embodiment, compounds of formula I **fgkc**, **fgbb** and **fgbc** are active against *S. pneumoniae*. In yet another embodiment, compounds of formula I are **fgba** and **fgqa** and are active against *S. aureus*. In still another embodiment, the compound of formula I is **fgna** and is active against *C. difficile*.

As demonstrated herein, the compounds of the invention inhibit GlcNAcases, such as bacterial GlcNAcases. For example, compound **BI.fgba** (Scheme 1) inhibits the GlcNAcase LytG, and has concentration-dependent bacteriostatic activity in the bacterial strain *B. subtilis*.




Scheme 1. BI.fgba

In certain embodiments, the compounds of the invention exhibit whole-cell antibiotic activity. In other embodiments, the compounds modulate an extracellular enzyme, do not contain a reactive warhead susceptible to cleavage, and their target does not act on highly variable substrates. Without wishing to be limited by any theory, the molecular resistance mechanisms of efflux pumps, rapid chemical inactivation, and target substrate modification may be ineffective against the compounds of the invention.

20 Compounds and Compositions

The invention includes a compound of formula I, or a salt or solvate thereof:



R₁ is selected from the group consisting of aryl and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₂ is selected from the group consisting of C₁-C₈ alkyl, C₃-C₈ cycloalkyl, allyl, propargyl,

homopropargyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, wherein the alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₃ is selected from the group consisting of C₃-C₈ cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl, aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₄ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₈ cycloalkyl, arylalkyl and heteroarylalkyl, wherein the alkyl, cycloalkyl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl); and

R₅ is H or methyl.


In certain embodiments, in R₁ has at least one substituent ortho to the carbonyl group α is selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl). In other embodiments, at least one substituent ortho to the carbonyl group α is selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br and I. In yet other embodiments, R₁ is selected from the group consisting of phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl and p-methoxyphenyl.

In certain embodiments, R₂ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, heteroaryl, aryl-(CH₂)_{1,2}-, and heteroaryl-(CH₂)_{1,2}-, wherein the alkyl, cycloalkyl, phenyl, heteroaryl, aryl-(CH₂)_{1,2}-, or heteroaryl-(CH₂)_{1,2}-group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, and NO₂. In other embodiments, R₂ is selected from the group consisting of C₁-C₆ alkyl, C₅-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, p-methoxyphenyl, benzyl, Ph(CH₂)₂-, Ph₂CHCH₂-, and Ph(CH₃)CH.


In certain embodiments, R₃ is selected from the group consisting of C₃-C₆ cycloalkyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, and p-methoxyphenyl.

In certain embodiments, R_4 is selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, benzyl, and phenyl- $(CH_2)_2$ -, wherein the alkyl, cycloalkyl, phenyl or benzyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_6 alkyl, OH, $O(C_1$ - C_6 alkyl), F, Cl, Br, and I.


5 In certain embodiments, the compound of formula (I) is selected from the group consisting of:




fgca




fgia




fgja




fgbd




fgkd




rgba




ogba




pgba




qgba




fhba




fiba




fbqb




fgka




fgna




fgqb




fgba




fgoa




fgbb




fgpa




fgkb




fgqa




fgqc




fgra




fgbc




fgla




fgta




fgkc




fgma




fgua




fgsa




fgva




fgwa




fgxa




MO2




MO3




MO4




rgkc (66%)




rgna (52%)




pgkc (48%)




rgka




rgoa




qgkc




ngkc (69%)




ogkc (72%)




fhka (65%)




fhkc (67%)




tgka (71%)




tgkc (74%)




ugkc (78%)




vgkc (53%)




faqa




faaAa




fhqa




fhaAa



fgqd



MJ02



The compounds of the invention have shown antibacterial activity against a variety of Gram-positive and Gram-negative bacteria including, but not limited to *B. subtilis* Lyt, *S. pneumonia*, *C. difficile*, and *S. aureus*.

In certain embodiments, the compound of formula I is selected from the group consisting of **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka**, **fgna**, **fgbb**, **fgqa** and **fgbc**. In one embodiment, the compound is **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** or **fgna**. These compounds have antibacterial activity against *B. subtilis* Lyt G. In another embodiment, the compound is **fgkc**, **fgbb**, or **fgbc**. These compounds have antibacterial activity against *S. pneumoniae*. In yet another embodiment, the compound is **fgba** or **fgqa**. These compounds have antibacterial activity against *S. aureus*. In another embodiment, the compound is **fgna**, which has antibacterial activity against *C. difficile*.

In certain embodiments, the salt of compound I is an acid addition salt and is selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic,

pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid, and any combinations thereof.

In certain embodiments, the salt is a base addition salt and is selected from the group consisting of calcium, magnesium, potassium, sodium, ammonium, zinc, a basic amine salt, and any combinations thereof, wherein the basic amine is selected from the group consisting of triethylamine, diisopropylethylamine, trimethylamine, N,N'-dibenzylethylene-diamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and any combinations thereof.

The invention further provides a pharmaceutical composition comprising at least one compound of the invention and a pharmaceutically acceptable carrier. In certain embodiments, the composition further comprises at least one additional antibacterial agent. In other embodiments, the at least one additional antibacterial agent comprises at least one agent selected from the group consisting of amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim. In yet other embodiments, the compound and the agent are co-formulated in the composition.

The compounds of the invention may possess one or more stereocenters, and each stereocenter may exist independently in either the (R) or (S) configuration. In one embodiment, compounds described herein are present in optically active or racemic forms. The compounds described herein encompass racemic, optically-active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In one embodiment, a mixture of one or more isomer is utilized as the therapeutic compound described herein. In another embodiment, compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis and/or separation of a mixture of enantiomers and/or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.

The methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), solvates, amorphous phases, and/or pharmaceutically acceptable salts of compounds having the structure of any compound of the invention, as well as metabolites and active metabolites of these compounds having the same type of activity. Solvates include

water, ether (*e.g.*, tetrahydrofuran, methyl tert-butyl ether) or alcohol (*e.g.*, ethanol) solvates, acetates and the like. In one embodiment, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, and ethanol. In another embodiment, the compounds described herein exist in unsolvated form.

5 In one embodiment, the compounds of the invention exist as tautomers. All tautomers are included within the scope of the compounds recited herein.

In one embodiment, the compounds of the invention exist as polymorphs. All polymorphs are included within the scope of the compounds recited herein.

In one embodiment, compounds described herein are prepared as prodrugs (see for example
10 Hacker, *et al.*, Pharmacology: Principles and Practice. Academic Press, Jun 19, 2009, pp. 216-217). A “prodrug” is an agent converted into the parent drug *in vivo*. In one embodiment, upon *in vivo* administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In another embodiment, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the
15 compound.

In certain embodiments, sites on, for example, the aromatic ring portion of compounds of the invention are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the aromatic ring structures may reduce, minimize or eliminate this metabolic pathway. Accordingly, in one embodiment, a prodrug is created by methods well known in the art, by which the appropriate substituent
20 to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is added, by way of example only, a deuterium, a halogen, or an alkyl group.

Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for
25 inclusion in the compounds described herein include and are not limited to ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{36}Cl , ^{18}F , ^{123}I , ^{125}I , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{32}P , and ^{35}S . In one embodiment, isotopically-labeled compounds are useful in drug and/or substrate tissue distribution studies. In another embodiment, substitution with heavier isotopes such as deuterium affords greater metabolic stability (for example, increased *in vivo* half-life or reduced dosage requirements). In yet another embodiment, substitution with positron emitting
30 isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , is useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

In one embodiment, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

5 Synthesis

The compounds described herein, and other related compounds having different substituents, are synthesized using techniques and materials described herein and techniques known in the art such as those described, for example, in Fieser & Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements
10 (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey & Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green & Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the
15 preparation of compounds as described herein are modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formula as provided herein.

Compounds described herein are synthesized using any suitable procedures starting from compounds that are available from commercial sources, or are prepared using procedures described herein or known in the art.

20 In one embodiment, reactive functional groups, such as hydroxyl, amino, imino, thio or carboxy groups, are protected in order to avoid their unwanted participation in reactions. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. In another embodiment, each protective group is removable by a different means. Protective groups that are cleaved under totally disparate reaction
25 conditions fulfill the requirement of differential removal.

In one embodiment, protective groups are removed by acid, base, reducing conditions (such as, for example, hydrogenolysis), and/or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and
30 Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl, in the presence of amines that are blocked with acid labile groups, such as t-butyl carbamate, or with carbamates that are both acid and base stable but hydrolytically removable.


In one embodiment, carboxylic acid and hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties are protected by conversion to simple ester compounds as exemplified herein, which include

5 conversion to alkyl esters, or are blocked with oxidatively-removable protective groups such as 2,4-dimethoxy benzyl, while co-existing amino groups are blocked with fluoride labile silyl carbamates.

Allyl blocking groups are useful in the presence of acid- and base- protecting groups since the former are stable and are subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid is deprotected with a palladium-catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and does not react. Once released from the resin, the functional group is

10 available to react.

Typically blocking/protecting groups may be selected from:



Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene & Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure.

The compounds of the invention may be prepared according to the general methodology illustrated in the synthetic schemes described below. The reagents and conditions described herein may be modified to allow the preparation of the compounds of the invention, and such modifications are known to those skilled in the art. The scheme included herein are intended to illustrate but not limit the chemistry and methodologies that one skilled in the art may use to make compounds of the invention.

Salts

The compounds described herein may form salts with acids, and such salts are included in the present invention. In one embodiment, the salts are pharmaceutically acceptable salts. The term “salts”
embraces addition salts of free acids that are useful within the methods of the invention. The term
“pharmaceutically acceptable salt” refers to salts that possess toxicity profiles within a range that affords
utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess
properties such as high crystallinity, which have utility in the practice of the present invention, such as for
example utility in process of synthesis, purification or formulation of compounds useful within the
methods of the invention.

Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid
or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic,
nitric, carbonic, sulfuric (including sulfate and hydrogen sulfate), and phosphoric acids (including
hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from
aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic
acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic,
tartaric, citric, ascorbic, glucuronic, maleic, malonic, saccharin, fumaric, pyruvic, aspartic, glutamic,
benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic,
ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-
toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, salicylic,
galactaric and galacturonic acid.

Suitable pharmaceutically acceptable base addition salts of compounds of the invention include,
for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as,
for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base
addition salts also include organic salts made from basic amines such as, for example, N,N' -
dibenzylethylene-diamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine
(N-methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound
by reacting, for example, the appropriate acid or base with the compound.

Methods

The invention provides a method of inhibiting a N-acetylglucosaminidase in a cell. In certain
embodiments, the method comprises contacting the cell with at least one compound of the invention. In
other embodiments, the cell is a bacterium, a fungus or a cancer cell. In yet other embodiments, the N-
acetylglucosaminidase comprises an autolysin.

The invention also provides a method of inhibiting a N-acetylglucosaminidase in the cytosol of a cell. In certain embodiments, the method comprises contacting the N-acetylglucosaminidase with at least one compound of the invention. In other embodiments, the N-acetylglucosaminidase is derived from a bacterium, a fungus or a cancer cell.

5 The invention further provides a method of treating or preventing a bacterial infection in a subject in need thereof. In certain embodiments, the method comprises administering a therapeutically effective amount of at least one compound of the invention to the subject.

In one embodiment of the methods of the invention described above, the bacterium is Gram-positive. In another embodiment, the Gram-positive bacterium is selected from the group consisting of
10 *Streptococcus sp.*, *Staphylococcus sp.*, *Enterococcus sp.*, *Corynebacterium sp.*, *Listeria sp.*, *Clostridium sp.* and *Bacillus sp.* In yet another embodiment, the Gram-positive bacterium is *Clostridium difficile* (also currently known as *Peptoclostridium difficile*), *Streptococcus pneumoniae*, *Staphylococcus aureus*, vancomycin intermediate resistance *S. aureus* (VISA), *Enterococcus faecalis*, vancomycin resistant enterococci (VRE), *Streptococcus pyogenes*, *Bacillus anthracis*, *Corynebacterium diphtheria* or *Bacillus*
15 *cereus*.

In one embodiment of the methods of the invention described above, the bacterium is Gram-negative. In another embodiment, the Gram-negative bacterium is selected from the group consisting of
20 *Salmonella sp.*, *Escherichia sp.*, *Klebsiella sp.*, *Acinetobacter sp.*, *Pseudomonas sp.*, *Vibrio sp.* and *Enterobacter sp.* In yet another embodiment, the Gram-negative bacterium is *Salmonella enterica*, *Salmonella typhi*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* or *Pseudomonas aeruginosa*.

In yet other embodiments, the subject is further administered at least one additional antibacterial agent. In yet other embodiments, the at least one additional antibacterial agent comprises at least one agent selected from the group consisting of amoxicillin, azithromycin, biaxin, biocef, cefaclor, cinoxacin,
25 ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim.

In certain embodiments, the compound of the invention and the additional agent are separately administered to the subject. In other embodiments, the compound and the agent are co-administered to
30 the subject. In yet other embodiments, the compound and the agent are co-formulated. In yet other embodiments, the compound is administered to the subject by at least one route selected from the group consisting of intravenous, oral, inhalational, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary and topical routes. In yet other embodiments, the subject is a mammal. In yet other embodiments, the mammal is a human. In yet other

embodiments, the method further comprises procuring the at least one compound of the invention for the subject.

Kits

5 The invention includes a kit comprising a compound of the invention, an applicator, and an instructional material for use thereof. The instructional material included in the kit comprises instructions for preventing or treating a disorder or disease contemplated within the invention in a subject. The instructional material recites the amount of, and frequency with which, the compound of the invention should be administered to the subject. In certain embodiments, the kit further comprises at least one
10 additional antibacterial agent.

Combination Therapies

 In certain embodiments, the compounds of the invention are useful in the methods of the invention in combination with at least one additional agent useful for treating or preventing bacterial
15 infection. This additional agent may comprise compounds identified herein or compounds, *e.g.*, commercially available compounds, known to treat, prevent or reduce the symptoms of bacterial infection.

 Non-limiting examples of additional agents contemplated within the invention include amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel,
20 enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim.

 A synergistic effect may be calculated, for example, using suitable methods such as, for example, the Sigmoid- $E_{\max}$ equation (Holford & Scheiner, 19981, Clin. Pharmacokinet. 6: 429-453), the equation of
25 Loewe additivity (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol. 114: 313-326) and the median-effect equation (Chou & Talalay, 1984, Adv. Enzyme Regul. 22:27-55). Each equation referred to above may be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and combination index curve, respectively.

30

Administration/Dosage/Formulations

 The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the subject either prior to or after the onset of a disease or disorder contemplated in the invention. Further, several divided dosages, as well as staggered dosages may be

administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

Administration of the compositions of the present invention to a patient, in particular a mammal, more particularly a human, may be carried out using known procedures, at dosages and for periods of time effective to treat a disease or disorder contemplated in the invention. An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the state of the disease or disorder in the patient; the age, sex, and weight of the patient; and the ability of the therapeutic compound to treat a disease or disorder contemplated in the invention. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for a therapeutic compound of the invention is from about 1 and 5,000 mg/kg of body weight/per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

In particular, the selected dosage level depends upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A medical doctor, *e.g.*, physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the invention are dictated

by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of a disease or disorder contemplated in the invention.

In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is advantageous to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

In one embodiment, the compounds/compositions of the invention are administered to the patient in dosages that range from one to five times per day or more. In another embodiment, the compositions of the invention are administered to the patient in range of dosages that include, but are not limited to, once every day, every two, days, every three days to once a week, and once every two weeks. It is readily apparent to one skilled in the art that the frequency of administration of the various combination compositions of the invention varies from individual to individual depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, the invention should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient is determined by the attending physician taking all other factors about the patient into account.

Compounds of the invention for administration may be in the range of from about 1 μ g to about 10,000 mg, about 20 μ g to about 9,500 mg, about 40 μ g to about 9,000 mg, about 75 μ g to about 8,500 mg, about 150 μ g to about 7,500 mg, about 200 μ g to about 7,000 mg, about 3050 μ g to about 6,000 mg, about 500 μ g to about 5,000 mg, about 750 μ g to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg, about 25 mg to about 1,500 mg, about 30 mg to about 1,000 mg, about 40 mg to about 900 mg, about 50 mg to about 800 mg, about 60 mg to

about 750 mg, about 70 mg to about 600 mg, about 80 mg to about 500 mg, and any and all whole or partial increments therebetween.

In some embodiments, the dose of a compound of the invention is from about 1 mg and about 2,500 mg. In some embodiments, a dose of a compound of the invention used in compositions described
5 herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some
embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less
10 than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.

In one embodiment, the present invention is directed to a packaged pharmaceutical composition
15 comprising a container holding a therapeutically effective amount of a compound of the invention, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or disorder contemplated in the invention.

Formulations may be employed in admixtures with conventional excipients, *i.e.*, pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous,
20 subcutaneous, enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like. They may also be combined where desired with other active agents, *e.g.*, other analgesic agents.

25 Routes of administration of any of the compositions of the invention include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the invention may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (*e.g.*, sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (*e.g.*, trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical,
30 intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays

for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present invention are not limited to the particular formulations and compositions that are described herein.

5 *Oral Administration*

For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets.

10 Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.

15 For oral administration, the compounds of the invention may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, polyvinylpyrrolidone, hydroxypropylcellulose or hydroxypropylmethylcellulose); fillers (*e.g.*, cornstarch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (*e.g.*, magnesium stearate, talc, or silica); disintegrates (*e.g.*, sodium starch glycollate); or wetting agents (*e.g.*, sodium lauryl sulphate). If
20 desired, the tablets may be coated using suitable methods and coating materials such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (*e.g.*, OPADRY™ OY Type, OY-C Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY™ White, 32K18400). Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically
25 acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters or ethyl alcohol); and preservatives (*e.g.*, methyl or propyl p-hydroxy benzoates or sorbic acid).

Granulating techniques are well known in the pharmaceutical art for modifying starting powders or other particulate materials of an active ingredient. The powders are typically mixed with a binder
30 material into larger permanent free-flowing agglomerates or granules referred to as a “granulation.” For example, solvent-using “wet” granulation processes are generally characterized in that the powders are combined with a binder material and moistened with water or an organic solvent under conditions resulting in the formation of a wet granulated mass from which the solvent may then be evaporated.

Melt granulation generally consists in the use of materials that are solid or semi-solid at room temperature (*i.e.* having a relatively low softening or melting point range) to promote granulation of powdered or other materials, essentially in the absence of added water or other liquid solvents. The low melting solids, when heated to a temperature in the melting point range, liquefy to act as a binder or
5 granulating medium. The liquefied solid spreads itself over the surface of powdered materials with which it is contacted, and on cooling, forms a solid granulated mass in which the initial materials are bound together. The resulting melt granulation may then be provided to a tablet press or be encapsulated for preparing the oral dosage form. Melt granulation improves the dissolution rate and bioavailability of an active (*i.e.* drug) by forming a solid dispersion or solid solution.

10 U.S. Patent No. 5,169,645 discloses directly compressible wax-containing granules having improved flow properties. The granules are obtained when waxes are admixed in the melt with certain flow improving additives, followed by cooling and granulation of the admixture. In certain embodiments, only the wax itself melts in the melt combination of the wax(es) and additives(s), and in other cases both the wax(es) and the additives(s) melt.

15 The present invention also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds of the invention, and a further layer providing for the immediate release of a medication for treatment of a disease or disorder contemplated in the invention. Using a wax/pH-sensitive polymer mix, a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release.

20 *Parenteral Administration*

As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by
25 application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.

30 Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multidose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions,

emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (*i.e.*, powder or granular) form for reconstitution with a suitable vehicle (*e.g.*, sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.

The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butanediol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

Topical Administration

An obstacle for topical administration of pharmaceuticals is the stratum corneum layer of the epidermis. The stratum corneum is a highly resistant layer comprised of protein, cholesterol, sphingolipids, free fatty acids and various other lipids, and includes cornified and living cells. One of the factors that limit the penetration rate (flux) of a compound through the stratum corneum is the amount of the active substance that can be loaded or applied onto the skin surface. The greater the amount of active substance which is applied per unit of area of the skin, the greater the concentration gradient between the skin surface and the lower layers of the skin, and in turn the greater the diffusion force of the active substance through the skin. Therefore, a formulation containing a greater concentration of the active substance is more likely to result in penetration of the active substance through the skin, and more of it, and at a more consistent rate, than a formulation having a lesser concentration, all other things being equal.

Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, and solutions or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of

the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.

Enhancers of permeation may be used. These materials increase the rate of penetration of drugs across the skin. Typical enhancers in the art include ethanol, glycerol monolaurate, PGML (polyethylene glycol monolaurate), dimethylsulfoxide, and the like. Other enhancers include oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone.

One acceptable vehicle for topical delivery of some of the compositions of the invention may contain liposomes. The composition of the liposomes and their use are known in the art (for example, see Constanza, U.S. Patent No. 6,323,219).

In alternative embodiments, the topically active pharmaceutical composition may be optionally combined with other ingredients such as adjuvants, anti-oxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifying agents, viscosifiers, buffering agents, preservatives, and the like. In another embodiment, a permeation or penetration enhancer is included in the composition and is effective in improving the percutaneous penetration of the active ingredient into and through the stratum corneum with respect to a composition lacking the permeation enhancer. Various permeation enhancers, including oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone, are known to those of skill in the art. In another aspect, the composition may further comprise a hydrotropic agent, which functions to increase disorder in the structure of the stratum corneum, and thus allows increased transport across the stratum corneum. Various hydrotropic agents such as isopropyl alcohol, propylene glycol, or sodium xylene sulfonate, are known to those of skill in the art.

The topically active pharmaceutical composition should be applied in an amount effective to affect desired changes. As used herein "amount effective" shall mean an amount sufficient to cover the region of skin surface where a change is desired. An active compound should be present in the amount of from about 0.0001% to about 15% by weight volume of the composition. In particular, it is advantageously present in an amount from about 0.0005% to about 5% of the composition; more particularly, it is advantageously present in an amount of from about 0.001% to about 1% of the composition. Such compounds may be synthetically-or naturally derived.

Buccal Administration

A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) of

the active ingredient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingredient. Such powdered, aerosolized, or aerosolized formulations, when
5 dispersed, preferably have an average particle or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein. The examples of formulations described herein are not exhaustive and it is understood that the invention includes additional modifications of these and other formulations not described herein, but which are known to those of skill in the art.

10 *Rectal Administration*

A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for rectal administration. Such a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.

Suppository formulations may be made by combining the active ingredient with a non-irritating
15 pharmaceutically acceptable excipient which is solid at ordinary room temperature (*i.e.*, about 20°C) and which is liquid at the rectal temperature of the subject (*i.e.*, about 37°C in a healthy human). Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.

Retention enema preparations or solutions for rectal or colonic irrigation may be made by
20 combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject. Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.

25 *Additional Administration Forms*

Additional dosage forms of this invention include dosage forms as described in U.S. Patents Nos. 6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms of this invention also include dosage forms as described in U.S. Patent Applications Nos. 20030147952; 20030104062; 20030104053; 20030044466; 20030039688; and 20020051820. Additional dosage forms
30 of this invention also include dosage forms as described in PCT Applications Nos. WO 03/35041; WO 03/35040; WO 03/35029; WO 03/35177; WO 03/35039; WO 02/96404; WO 02/32416; WO 01/97783; WO 01/56544; WO 01/32217; WO 98/55107; WO 98/11879; WO 97/47285; WO 93/18755; and WO 90/11757.

Controlled Release Formulations and Drug Delivery Systems

In one embodiment, the formulations of the present invention may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.

5 The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer than the same amount of agent administered in bolus form.

10 For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use the method of the invention may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.

15 In one embodiment of the invention, the compounds of the invention are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.

The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that may, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.

20 The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.

The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.

25 As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.

30 As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.

Dosing

The therapeutically effective amount or dose of a compound of the present invention depends on the age, sex and weight of the patient, the current medical condition of the patient and the progression of a

disease or disorder contemplated in the invention. The skilled artisan is able to determine appropriate dosages depending on these and other factors.

A suitable dose of a compound of the present invention may be in the range of from about 0.01 mg to about 5,000 mg per day, such as from about 0.1 mg to about 1,000 mg, for example, from about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day. The dose may be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage may be the same or different. For example, a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses.

It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on.

In the case wherein the patient's status does improve, upon the doctor's discretion the administration of the inhibitor of the invention is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (*i.e.*, a "drug holiday"). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the disease or disorder, to a level at which the improved disease is retained. In one embodiment, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms and/or infection.

The compounds for use in the method of the invention may be formulated in unit dosage form. The term "unit dosage form" refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form may be for a single daily dose or one of multiple daily doses (*e.g.*, about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.

Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD₅₀ and ED₅₀. The data obtained from cell culture assays and animal studies are optionally used in formulating a range of dosage for use in human. The dosage of such compounds lies advantageously within a range of circulating concentrations that include the ED₅₀ with minimal toxicity. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this invention and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, *e.g.*, nitrogen atmosphere, and reducing/oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.

It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present invention. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.

The following examples further illustrate aspects of the present invention. However, they are in no way a limitation of the teachings or disclosure of the present invention as set forth herein.

EXAMPLES

The invention is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these Examples, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Materials and Methods

Compounds were purchased from standard suppliers and used without further purification. Thin layer chromatography was carried out on Merck silica gel 60 F254 precoated glass plates. Spots were detected by UV light and immersion in *p*-anisaldehyde stain or potassium permanganate stain.

Evaporation of solvents was performed under reduced pressure at 30-40 °C. NMR spectra were recorded on Bruker Avance III HD Ascend 600 MHz and Bruker Avance Ultra-Shield 400 MHz. ¹H, ¹³C, COSY, HSQC and ¹³C-DEPT135 were referenced to residual solvent peaks. The coupling constants are given in [Hz] and chemical shifts in [ppm]. Electrospray ionization (ESI) and fast atom bombardment (FAB) mass spectra were obtained using JEOL JMS-600H double focusing magnetic sector mass spectrometer for HRMS and Thermo LCQ Deca XP Max ion trap mass spectrometer with Shimadzu HPLC system for LRMS in positive mode. The Ugi products as well as the glycosyl triazoles may exist as mixtures of rotamers (and diastereomeric mixtures in the case of the triazoles), resulting in multiple peaks in the NMR spectra. Compounds may also exist as mixtures of cis/trans amide isomers, resulting in multiple peaks in the NMR spectra. Partial assignments are provided.

General Procedure for Ugi Reaction:

A 0.1 M solution of each reactant (amine, aldehyde, acid and isocyanide) in MeOH was prepared. Amine (5.0 mL) and aldehyde (5.0 mL) were stirred in a capped scintillation vial for 30 min. at 35-40°C maintained using a drilled out aluminum block. Isocyanide (5.0 mL) was added to this solution and the reaction mixture was stirred for additional 20 minutes at 50°C. Lastly the acid (5.0 mL of 0.1 M) was added and the reaction mixture was continuously stirred at 55°C for 3-5 h. The progress of the reaction was monitored by TLC using UV-light and *p*-anisaldehyde or potassium permanganate for visualization. Upon consumption of the starting materials and complete product formation according to TLC, the solvent was removed *in vacuo* and the crude product was dried under high vacuum. An NMR and ESI-LRMS were obtained of the crude product. Depending on purity of the crude product, it was either taken forward to the next reaction or it was purified using an acid/base extraction. In case of incomplete reaction, the solvent was removed *in vacuo* and the residue was dried under high vacuum for at least 30 minutes to ensure that all methanol was evaporated. The dried residue was dissolved in 30 mL of ethyl acetate. The organic layer was then extracted with 1 M HCl, H₂O, saturated NaHCO₃, H₂O and brine (2x). The organic layer was dried with Na₂SO₄, the solvent was evaporated *in vacuo* and the residue was dried under high vacuum.

General Procedure for 'Click' Reaction:

The reactions were run using stock solutions of the 2-*N*-acetylamido-2-deoxy-β-D-glucopyranosyl azide (Hong, *et al.*, 2007, J. Am. Chem. Soc. 129:10966-7), the catalyst system and the solvent mixture.

For a 20 mg scale of (1) (0.081 mmol): The Ugi-derived dipeptide (0.11 mmol, 1.3 eq.) was dissolved in a 1:1 MeCN/H₂O solution (4.05 mL, 26 mM). To this solution CuSO₄•H₂O (10 μL of 0.8M

CuSO₄•H₂O in H₂O, 10 mol%, 8.10 μmol) and Cu-powder (10.00 μL of a 5.7M Cu powder suspension in H₂O, 0.06 mmol, 0.7 eq.) was added. Lastly **1** (71 μL of a 1.1M solution in H₂O, 0.08 mmol) was added and the reaction was stirred at 45°C in a capped scintillation vial in an aluminum block until TLC showed completion. At 4 hours into the reaction, an additional 5 μL of both the CuSO₄•H₂O and Cu-powder

solutions were added.

For the TLC the following solvents could be applied: 5:1 DCM/MeOH, 3:1 DCM/MeOH or 2:1 DCM/MeOH. For visualization of the TLC p-anisaldehyde stain or potassium permanganate stain was used.

After completion of the reaction 3-4 spatulas of CupriSorb™ and H₂O (2-3 mL) were added and the mixture was slowly stirred at room temperature overnight. The content was carefully transferred to a new scintillation vial, avoiding the CupriSorb™ beads. MeOH was used for rinsing the CupriSorb™ beads and the reaction vial and the MeCN/H₂O solvent mixture was removed using a centrifuge. The residue was dissolved in 20:1 DCM/MeOH (1-2 mL) and purified with a silica-plug. After approximately two test tubes in which the unreacted dipeptide was collected, the solvent was switched to 5:1

DCM/MeOH in order to elute the product. Collected fractions were tested with ESI-MS and TLC for any residual alkyne (20:1 DCM/MeOH, potassium permanganate stain) or **1** (5:1 DCM/MeOH, p-anisaldehyde stain or potassium permanganate stain). Clean product fractions were collected, the solvent residue was removed *in vacuo* and the product was dried under high vacuum.

20 Antimicrobial Testing:

1. Bacterial Strains and Growth Conditions

Bacillus subtilis ATCC 11775 was plated on agar from a 20% glycerol stock solution stored at -80°C. Inoculated plates were then incubated at 37 °C under aerobic conditions for 16 hours. Single cultures were transferred to Nutrient Broth (NB) and cultured for 16 hours under the same conditions.


Samples of first passage cultures that exhibited growth were transferred again to fresh NB media and cultured for 6 hours under identical conditions. Second passage cultures were standardized to O.D._{600nm} = 1.0.

2. Antimicrobial Screening Assay

The resazurin microtiter assay procedure described by Palomino and coworkers was used for assessing antimicrobial activity (Palomino, *et al.*, 2002, *Antimicrob. Agents Chemother.* **46**:2720–2722). The assay was performed in LB broth. Resazurin sodium salt powder was prepared in distilled water and filter sterilized at 0.001% (w/v) for MIC assays and at 0.01% (w/v) for single concentration assays. Compounds were first screened in MIC assays to assess whether growth inhibition was dependent on inhibitor concentration. The plates were incubated for 30 min under aerobic conditions. Growth controls


containing no inhibitory compound, sterility controls without inoculation, and controls containing a known antibiotic, chloramphenicol, were also included. The inoculum was prepared from second passage cultures in Nutrient Broth (NB) and standardized to $O.D._{600nm} = 1.0$ and the wells inoculated with a 1:20 dilution. Serial two-fold dilutions of each compound in 100 μ L of medium were prepared directly in 96 well plates at concentrations ranging from 250 μ M to 7 μ M. After incubation 30 μ L of resazurin solution was added to each well and incubated for 30 min. A change in color from blue to pink indicated reduction of resazurin, and therefore bacterial growth. Minimum inhibitory concentration (MIC) was determined as the lowest drug concentration that prevented the color change from blue to pink. Inhibition was quantified by observation of color change. Later studies were carried out at a single inhibitor concentration of 250 μ M. The plates were incubated for 4 h under aerobic conditions with the same controls. After incubation 30 μ L of resazurin solution was added to each well and incubated for 60 min. Inhibition was quantified by fluorescence readings from plate reader SAFIRE, Firmware: V 2.20 08/02 Safire. Excitation wavelength set to 560 nm, emission wavelength set to 590 nm. Well containing dye and non-inoculated cells was used as gain set. Plates were held at 37 °C and fluorescence measurements were taken at 0, 5, 10, 20, 30, and 60 min after addition of dye. Lower fluorescence values correlate to greater degrees of inhibition.

Example 1: Ugi Reaction Products.




ngba: Yield: 171 mg (88%, 0.44 mmol), yellow solid. 1H NMR (400 MHz, Acetone- d_6) δ [7.85-7.78 (m); 7.59-6.94 (m, 5H, aromatic, NH-18)], [5.01 (dd, $J = 17.4, 2.6$ Hz); 4.90-4.69 (m); 4.56 (dd, $J = 17.4, 2.9$ Hz); 3.74-3.62 (m), 2H, 13], [4.90-4.69 (m); 3.74-3.62 (m), 1H, 12], 3.35-3.05 (m, 2H, 22), 2.73-2.57 (m, 1H, 21), 2.23-2.07 (m, 1H, 15), [1.94-0.95 (m); 0.95-0.83 (m), 5H, 20, 19, 24, 23, 26], 1.94-0.95 (m, 4H, 25, 27), 0.95-0.83 (m, 3H, 28) ppm.

ogba: Yield: 191 mg (88%, 0.44 mmol), yellow solid. ^1H NMR (400 MHz, Acetone- d_6) δ [7.78 (dd, J = 7.6, 1.9 Hz); 7.70-7.56 (m); 7.52-7.29 (m); 7.26 (dd, J = 7.5, 1.7 Hz); 7.18 (dd, J = 7.3, 2.0 Hz), 4H, aromatic], [5.04 (dd, J = 17.4, 2.6 Hz); 4.90-4.75 (m); 4.59 (d, J = 2.5 Hz); 4.58-4.56 (m); 4.55 (d, J = 2.5 Hz); 4.53 (d, J = 2.5 Hz); 3.75-3.61 (m), 2H, 13], [4.90-4.75 (m); 3.75-3.61 (m), 1H, 12], 3.35-3.05 (m, 2H, 24), 2.74-2.56 (m, 1H, 21), 2.22-2.13 (m, 1H, 14), [1.80-0.98 (m); 0.96-0.81 (m), 14H, 17, 18, 22, 23, 25, 26, 27], 0.96-0.81 (m, 3H, 28) ppm.



pgba: Yield: 179 mg (93%, 0.47 mmol), yellow solid. ^1H NMR (600 MHz, Chloroform- d) δ [9.61 (d, J = 1.4 Hz); 8.07-8.03 (m); 7.62 (d, J = 8.2 Hz); 6.97-6.89 (m), 4H, aromatic], 6.97-6.89 (m, 4H, NH-19), [4.44-4.25 (m); 4.04-3.90 (m), 3H, 11, 12], [3.87 (s); 3.85 (s), 3H, 29], 3.24 (q, J = 6.7 Hz, 2H, 23), 2.32 (s, 1H, 20), 2.09-1.99 (m, 1H, 13), [1.83-1.62 (m); 1.38-1.12 (m), 6H, 21, 22, 24], 1.48 (p, J = 7.1 Hz, 2H, 25), 1.38-1.12 (m, 2H, 26), 1.04-0.84 (m, 7H, 16, 17, 27) ppm.

qgba: Yield: 176 mg (91%, 0.46 mmol), yellow solid. ^1H NMR (600 MHz, Acetone- d_6) δ [7.43-7.14 (m); 7.08-6.97 (m), 5H, 2, 3, 5, 7, NH-19], [4.86-4.40 (m); 4.28-4.15 (m); 3.97-3.89 (m); 2H, 12], [4.86-4.40 (m); 3.65 (d, J = 11.0 Hz), 1H, 11], 3.82 (3H, 29), 3.33-3.08 (m, 2H, 23), 2.64-2.52 (m, 1H, 20), 2.19-2.08 (m, 1H, 13), [1.81-1.59 (m); 1.30-1.14 (m); 1.08-0.95 (m); 0.85-0.66 (m), 10H, 16, 17, 21, 22, 24], 1.56-1.45 (m, 2H, 25), 1.44-1.30 (m, 2H, 26), 0.91 (t, J = 7.3 Hz, 3H, 27) ppm.




fdba: Yield: 205 mg (88%, 0.44 mmol), yellow solid. ^1H NMR (400 MHz, Acetone- d_6) δ [8.18-7.71 (m); 7.57-7.01 (m), 4H, 2, 3, 5, 8], 7.57-7.01 (m, 1H, NH-18), 5.19-3.50 (m, 3H, 12, 13), 3.43-3.04 (m, 2H, 20), 2.81-2.45 (m, 2H, 14, 19), 1.86-1.09 (m, 12H, 21, 22, 24, 25, 26, 27), 1.10-0.61 (m, 3H, 23) ppm.

5

fiba: Yield: 59 mg (25%, 0.125 mmol), yellow solid. ^1H NMR (600 MHz, Acetone- d_6) δ [8.01-7.88 (m); 7.80-7.07 (m), 9H, 1, 3, 6, 7, 16, 17, 21, 22, 24], 7.80-7.07 (m, 1H, NH-19), [6.25 (s); 6.04 (s); 5.62 (s); 5.39-5.13 (m), 1H, 11], 4.62-3.72 (m, 2H, 12), 3.37-3.09 (m, 2H, 23), [2.24-2.13 (m); 2.04-1.94 (m), 1H, 20], [1.56-1.41 (m); 1.39-1.32 (m), 2H, 25], [1.39-1.32 (m); 1.32-1.20 (m), 2H, 26], 0.93-0.83 (m, 3H, 27) ppm.

10




rgba: Yield: 171 mg (96%, 0.48 mmol), yellow solid. ^1H NMR (600 MHz, Acetone- d_6) δ [8.09-8.02 (m); 7.64-7.00 (m), 5H, 2, 3, 4, 5, 7], 7.64-7.00 (m, 1H, NH-19), 4.90-4.40 (m, 1H, 11), [4.90-4.40 (m); 4.21-4.13 (m); 4.02-3.78 (m), 2H, 12], 3.29-3.12 (m, 2H, 23), 2.89-2.55 (m, 1H, 20), 2.25-2.09 (m, 1H, 13), [1.83-1.58 (m); 1.30-0.96 (m), 10H, 16, 17, 21, 22, 24], 1.55-1.43 (m, 2H, 25), 1.35 (h, $J = 7.2$ Hz, 2H, 26), 0.91 (t, $J = 7.4$ Hz, 3H, 27).

15


fgbd: Yield: 296 mg (54%, 0.54 mmol), yellow solid. ^1H NMR (600 MHz, Chloroform- d) δ 8.79 (s, 1H, NH-19), [8.31-8.22 (m); 7.88-7.65 (m); 7.47-7.32 (m); 7.16-7.10 (m), 11H, 1, 2, 4, 7, 25, 28-33], 5.23-

5.13 (m, 1H, 11), [4.53 (d, $J = 18.8$ Hz); 3.80 (d, $J = 18.8$ Hz), 2H, 12], 2.37-2.27 (m, 1H, 13), 2.18 (s, 1H, 20), [2.03-1.69 (m); 1.47-1.31 (m); 1.23-1.09 (m); 0.92-0.77 (m), 10H, 16, 17, 21, 22, 24] ppm.



fgkd: Yield: 275 mg (46%, 0.46 mmol), yellow solid. ^1H NMR (600 MHz, Chloroform- d) δ [8.41 (d, $J = 2.0$ Hz); 7.89-7.85 (m); 7.82-7.79 (m); 7.79-7.75 (m); 7.62-7.58 (m); 7.45-7.41 (m); 7.39-7.35 (m); 7.24-7.20 (m); 7.14-7.10 (m), 1H, 1, 2, 4, 7, 23, 26-31], 3.53 (d, $J = 11.1$ Hz, 1H, 11), 3.23 (tt, $J = 11.8, 3.6$ Hz, 1H, 12), 3.01 (dtt, $J = 11.5, 3.4$ Hz, 1H, 13), [2.02-1.30 (m); 1.24-0.75 (m), 20H, 15, 16, 19, 20, 22, 32-36] ppm.

10 Example 2: Click Reaction Products.




BIngba: Yield: 47 mg (91%, 0.074 mmol), white solid. ^1H NMR (600 MHz, Methanol- d_4) δ 8.40-7.90 (m, 1H, 9), 7.82-7.15 (m, 5H, 24, NH-31, 21, 23, 22), 5.89-5.67 (m, 1H, 1), [5.48-4.88 (m); 4.48-4.41 (m), 2H, 11], 4.83-4.49 (m, 1H, 12), 4.35-4.02 (m, 1H, 2), [3.94-3.84 (m), 3.80-3.61 (m), 2H, 6], 3.80-

10




20


81.48, 81.40, 81.28- **4 or 5**], [76.75, 76.35, 75.84, 75.74- **3**], [71.76, 71.55- **4 or 5**], [69.72, 68.51, 65.06- **12**], [62.81, 62.60- **6**], [57.28, 56.88, 56.46- **2**], [40.33, 40.25- **14**], [40.21, 40.11- **11**], [39.48, 39.38, 39.11, 38.88, 38.26- **25**], [33.32, 33.26, 32.67, 32.48, 32.36, 32.34, 32.32, 32.17, 31.63, 30.93, 30.78- **15**], [27.57, 27.20, 27.16, 27.10, 26.82, 26.72, 26.61- **26-30**], [23.09, 22.95, 22.85, 22.82- **8**], [21.52, 21.45, 21.37- **16**], [14.28, 14.23, 14.20- **17**] ppm. ESI(+)-HRMS (*m/z*): Calcd for C₃₀H₄₃BrN₆O₇ [M+H]⁺ 679.2449, found 679.2445.




BLpgba: Yield: 33 mg (65%, 0.053 mmol), white solid. ¹H NMR (600 MHz, Methanol-*d*₄) δ 8.36-7.66 (m, 2H, **9**, NH-**31**), 7.53-7.27 (m, 2H, **20**, **24**), 7.01 (d, *J* = 8.2 Hz, 2H, **21**, **23**), 5.86-5.75 (m, 1H, **1**), 5.53-4.56 (m, 3H, **11**, **12**), 4.39-4.09 (m, 1H, **2**), [3.99-3.87 (m); 3.82-3.65 (m), 2H, **6**], 3.87 (s, 3H, **32**), 3.82-3.65 (m, 1H, **3**), 3.62-3.51 (m, 2H, **4**, **5**), 3.28-3.11 (m, 2H, **14**), 2.17 (dd, *J* = 32.6, 16.8 Hz, 1H, **25**), 1.79 (s, 3H, **8**), [1.75-1.62 (m); 1.35-1.03 (m); 0.90-0.59 (m), 10H, **30**, **26**, **29**, **27**, **28**], 1.58-1.45 (m, 2H, **15**), 1.44-1.35 (m, 2H, **16**), 0.98 (q, *J* = 7.4 Hz, 3H, **17**) ppm. ¹³C NMR (151 MHz, Methanol-*d*₄) δ [175.43, 173.35, 172.10, 172.02- **7**, **13**, **18**], [162.56, 162.46- **22**], 129.82 (**20**, **24**), 129.35 (**10**), 129.32 (**19**), 124.15 (**9**), 115.12 (**21**, **23**), [87.97, 87.92- **1**], 81.23 (**4** or **5**), 75.64 (**3**), [71.44, 71.41- **4** or **5**], [62.42, 62.39- **6**], [56.98, 55.96- **2**], [55.88, 55.86- **32**], [40.17, 40.05- **14**], 39.18 (**25**), [32.34, 32.31- **15**], [27.24, 26.89, 26.87, 26.72- **26-30**], [22.78, 22.66- **8**], [21.22, 21.19, 21.07- **16**], [14.12, 14.10- **17**] ppm. ESI(+)-HRMS (*m/z*): Calcd for C₃₁H₄₆N₆O₈ [M+H]⁺ 631.3377, found 631.3449.




Bl.qgba: Yield: 41 mg (80%, 0.065 mmol), white solid. ^1H NMR (600 MHz, Methanol- d_4) δ 8.39-7.75 (m, 1H, 9), [8.39-7.75 (m); 7.65-6.77 (m), 1H, NH-31], 7.65-6.77 (m, 4H, 21-24), 5.89-5.67 (m, 1H, 1), [5.30-4.92 (m); 4.85-4.36 (m), 2H, 11], [4.85-4.36 (m); 3.66-3.60 (m), 1H, 12], 4.31-3.98 (m, 1H, 2), [3.96-3.88 (m); 3.78-3.66 (m), 2H, 6], 3.87-3.79 (m, 3H, 32), 3.78-3.66 (m, 1H, 3), 3.60-3.40 (m, 2H, 4, 5), 3.37-2.99 (m, 2H, 14), 2.42-2.11 (m, 1H, 25), [2.11-1.95 (m); 1.76-1.00 (m); 0.88-0.49 (m), 1H, 15, 16, 26-30], 1.95-1.76 (m, 3H, 8), 1.00-0.89 (m, 3H, 17) ppm. ^{13}C NMR (151 MHz, Methanol- d_4) δ [173.40, 173.33, 173.29, 173.00- 7, 13, 18], 156.59 (20), 135.18 (10), [132.17, 132.04, 129.72, 129.29, 123.37, 122.05, 121.95, 112.77, 112.57- 9, 21-24], 126.89 (19), 88.11 (1), [81.41, 81.31, 81.16- 4 or 5], [76.04, 75.66, 75.55- 3], 71.48 (4 or 5), 68.28 (12), [62.47, 62.44- 6], [57.29, 56.95, 56.58, 56.40- 2], [56.23, 56.17- 32], 40.41 (14), [40.28, 39.99- 11], [39.41, 39.25, 38.71, 37.94- 25], [32.45, 32.42- 15], [31.75, 31.64, 30.91, 27.48, 27.16, 26.94, 26.67, 26.59- 26-30], [22.86, 22.68, 22.65- 8], [21.29, 21.22, 21.17- 16], [14.16, 14.10- 17] ppm. ESI(+)-HRMS (m/z): Calcd for $\text{C}_{31}\text{H}_{46}\text{N}_6\text{O}_8$ $[\text{M}+\text{H}]^+$ 631.3377, found 631.3442.




Bl.fhba: Yield: 42 mg (73%, 0.059 mmol), white solid. ^1H NMR (600 MHz, Methanol- d_4) δ [8.37-7.98 (m); 7.84-7.65 (m), 2H, 9, NH-30], [7.97-7.87 (m); 7.55-7.06 (m), 4H, 21-24], 5.93-5.71 (m, 1H, 1), 5.53-5.39 (m); 5.25-4.92 (m); 4.47-4.39 (m), 2H, 11], [4.79-4.47 (m); 3.68-3.49 (m), 1H, 12], 4.38-4.07 (m, 1H, 2), [3.96-3.87 (m); 3.82-3.68 (m), 2H, 6], 3.82-3.68 (m, 1H, 3), 3.68-3.49 (m, 2H, 4, 5), 3.39-3.04 (m, 2H, 14), 2.94-2.57 (m, 1H, 25), [2.03-1.85 (m); 1.75-1.00 (m); 0.93-0.81 (m), 12H, 15, 16, 26-29], 1.84-1.76 (m, 3H, 8), 1.00-0.94 (m, 3H, 17) ppm. ^{13}C NMR (151 MHz, Methanol- d_4) δ [173.89, 172.91, 172.24- 7, 13, 18], [141.25, 140.86, 140.44, 132.11, 131.84, 131.71, 129.63, 129.46, 129.12, 128.60- 10, 19, 21-24], 123.73 (9), [93.39, 93.02- 20], [88.28, 87.90, 87.54- 1], [81.48, 81.32, 81.16- 4 or 5], [76.93, 76.30, 75.73, 75.63, 75.38- 3], [71.68, 71.38- 4 or 5], [68.67, 67.09, 64.43- 12], [62.68, 62.45- 6], [57.36, 57.11, 56.56, 56.45, 56.27- 2], [42.36, 42.33, 41.81, 41.58- 25], [40.34, 40.31- 11], [40.16, 40.04- 14], [32.93, 32.54, 32.40, 32.37, 32.18, 32.15, 31.68, 31.61, 31.04, 30.93, 30.48, 26.34, 26.15, 26.04, 25.93, 25.83, 25.73, 25.60- 15, 26-29], [22.99, 22.89, 22.81, 22.70- 8], [21.42, 21.30- 16], [14.15, 14.09, 14.07- 17] ppm. ESI(+)-HRMS (m/z): Calcd for $\text{C}_{29}\text{H}_{41}\text{N}_6\text{O}_7$ [$\text{M}+\text{H}$] $^+$ 713.2081, found 713.2153.



BL.fiba: Yield: 54 mg (92%, 0.075 mmol), white solid. ^1H NMR (600 MHz, Methanol- d_4) δ 8.19-7.03 (m, 10H, **21-24, 26-30**), [6.11-5.99 (m); 5.50-5.40 (m); 5.24-5.21 (m), 1H, **12**], 5.79-5.60 (m, 1H, **1**), [5.11-4.90 (m), 4.84-4.78 (m), 4.52-4.19 (m), 2H, **11**], 4.18-3.96 (m, 1H, **2**), [3.96-3.86 (m); 3.80-3.69 (m), 2H, **6**], [3.80-3.69 (m); 3.69-3.59 (m), 1H, **3**], 3.58-3.45 (m, 2H, **4, 5**), 3.29-3.09 (m, 2H, **14**), 2.01-1.72 (m, 3H, **8**), 1.64-1.20 (m, 4H, **15, 16**), 0.91 (t, $J = 7.4, 2.6$ Hz, 3H, **17**) ppm. ^{13}C NMR (151 MHz, Methanol- d_4) δ [173.70, 173.52, 173.37, 173.18, 171.60- **7, 13, 18**], [142.83, 142.71- **19**], [140.95, 140.76, 132.10, 132.06, 131.86, 131.47, 131.26, 131.17, 130.25, 130.12, 130.00, 129.95, 129.82, 129.54, 129.51, 128.94, 128.44, 128.36- **21-24, 26-30**], 136.52 (**25**), [135.05, 134.95- **10**], [124.23, 123.50, 123.24- **9**], [93.63, 93.47- **20**], [87.99, 87.78, 87.43- **1**], [81.28, 81.20, 81.16- **4 or 5**], [76.47, 75.74, 75.56- **3**], [71.58, 71.40, 71.37- **4 or 5**], [67.73, 65.73- **12**], [62.61, 62.50, 62.42- **6**], [57.27, 56.50- **7**], [41.80, 41.56- **11**], [40.50, 40.27, 40.13- **14**], [32.21, 32.10- **15**], [23.00, 22.92, 22.84, 22.79- **8**], [21.22, 21.16, 21.10, 21.08- **16**], [14.11, 14.05, 13.99- **17**] ppm. ESI(+)-HRMS (m/z): Calcd for $\text{C}_{30}\text{H}_{37}\text{IN}_6\text{O}_7$ [M+H] $^+$ 721.1768, found 721.1836.





BL.rgba: Yield: 39 mg (80%, 0.065 mmol), white solid. ^1H NMR (600 MHz, Methanol- d_4) δ 8.37-7.66 (m, 2H, 9, 31), 7.60-7.29 (m, 5H, 20-24), 5.87-5.70 (m, 1H, 1), [5.27-4.92 (m); 3.81-3.62 (m), 1H, 12], [5.27-4.92 (m); 4.79-4.47 (m), 2H, 11], 4.37-4.10 (m, 1H, 2), [3.94-3.85 (m); 3.81-3.62 (m), 2H, 6], 3.81-3.62 (m, 1H, 3), 3.62-3.49 (m, 2H, 4, 5), 3.25-3.09 (m, 2H, 14), 2.23 (t, J = 50.6 Hz, 1H, 25), [1.87-1.79 (m); 1.74-1.44 (m); 1.33-0.98 (m); 0.93-0.55 (m), 10H, 26-30], 1.77 (t, J = 13.7 Hz, 3H, 8), 1.74-1.44 (m, 2H, 15), 1.43-1.33 (m, 2H, 16), 0.96 (q, J = 7.3 Hz, 3H, 17) ppm. ^{13}C NMR (151 MHz, Methanol- d_4) δ 173.36 (7, 13, 18), [133.88, 131.06, 130.94, 129.91, 129.88, 127.85, 125.15-9, 10, 19-24], 88.09 (1), 81.28 (4 or 5), 75.68 (3), 71.50 (4 or 5), 69.13 (12), 62.46 (6), [57.07, 56.20-2], [44.26, 43.71-11], 40.15 (14), 39.16 (25), 32.34 (15), [27.13, 26.89, 26.86-26-30], [22.78, 22.67-8], [21.21, 21.18-16], 14.07 (17) ppm. ESI(+)-HRMS (m/z): Calcd for $\text{C}_{30}\text{H}_{44}\text{N}_6\text{O}_7$ [$\text{M}+\text{H}$] $^+$ 601.327, found 601.3344.



fgca: ^1H NMR (600 MHz, Acetone- d_6) δ 7.97-7.06 (m, 9H, **aromatic**), [7.03 (br s); 6.96 (br s); 1H, NH-25], [5.28 (d, J = 10.7 Hz); 5.25 (d, J = 11.0 Hz); 5.13 (d, J = 14.8); 4.97 (d, J = 15.0 Hz); 4.89 (d, J = 17.1 Hz); 4.79 (br); 4.63 (d, J = 15.4 Hz); 4.39 (br); 4.28 (br), 2H, **26**], [3.79 (d, J = 10.5 Hz); 3.70 (d, J = 10.1 Hz), 1H, **11**], 3.34-3.05 (m, 2H, **16**), 1.98-1.94 (m, 1H, **13**), 1.94-0.67 (m, 17H, **16, 17, 18, 19, 20, 21, 22, 23, 24**). ^{13}C NMR (151 MHz, Acetone) δ [172.6, 172.2, 170.7, 170.1 - **8, 12**], [144.1, 143.2, 138.4 - **4, 27**], [141.1, 140.8, 140.7, 131.2, 131.0, 130.8, 130.0, 129.4, 129.2, 128.9, 128.8, 128.72, 128.67, 128.0, 127.5, 127.3 - **1, 2, 3, 6, 28, 29, 30, 31, 32**], 93.8 (**5**), [69.0, 67.8 - **11**], [51.0, 47.9, 47.1 - **26**], 39.6 (**16**), 37.7 (**13**), [33.4, 32.5, 32.2, 32.1, 31.6, 31.0, 30.5, 30.4, 30.3, 27.1, 26.89, 26.85, 26.8, 26.7, 26.5, 26.4, 26.3, 26.2, 21.0, 20.9, 20.5 - **17, 18, 20, 21, 22, 23, 24**], 14.1 (**19**). FAB-HRMS (m/z): calcd. For $\text{C}_{26}\text{H}_{33}\text{IN}_2\text{O}_2 + \text{H}$: 533.1665, found 533.1655.

fgja: ^1H NMR (600 MHz, Acetone- d_6) δ [8.10-7.75 (m); 7.59-7.09 (m), 4H, **aromatic**], [7.59-7.09 (m); 7.00 (br s); 6.94 (br s); 1H, NH-23], [6.17-6.08 (m); 5.85-5.60 (m), 1H, **12**], [5.31-5.25 (m); 5.19-5.05 (m); 4.95-4.53 (m), 2H, **22**], [5.19-5.05 (m); 4.95-4.53 (m); 3.71-3.37 (m), 1H, **13**], 4.48-3.76 (m, 2H, **11**), 3.28-3.05 (m, 2H, **24**), [2.37-2.13 (m); 1.83-0.57 (m), 17H, **15, 16, 17, 18, 19, 25, 26, 27**], 1.99-1.84 (m, 1H, **14**). ^{13}C NMR (151 MHz, Acetone) δ [172.1, 171.5 - **8, 20**], 144.0 (**4**), [142.2, 140.5, 140.1, 132.0, 131.0, 130.6, 129.0, 128.9, 128.6 - **1, 2, 3, 6**], [136.6, 135.6, 133.9 - **12**], [117.4, 116.4 - **22**], 109.1 (**5**), [80.0, 68.4, 67.1, 62.4 - **13**], [49.5, 46.8 - **11**], [39.4, 36.9-24], [33.1, 32.4, 32.2, 32.1, 31.2, 30.9, 30.3, 28.7, 28.6, 27.1, 26.9, 26.84, 26.76, 26.7, 26.6, 26.5, 26.4, 26.2, 26.1, 25.7, 21.0, 20.8-14, **15, 16, 17, 18, 19, 25, 26**], 14.1 (**27**). FAB-HRMS (m/z): calcd. For $\text{C}_{22}\text{H}_{31}\text{IN}_2\text{O}_2 + \text{H}$: 483.1509, found 483.1507.




fgja: ^1H NMR (600 MHz, Acetone- d_6) δ [7.94-7.82 (m); 7.53-7.38 (m); 7.34-7.10 (m), 4H, **aromatic**], [7.56 (br s); 7.34-7.10 (m); 6.98-6.91 (m), 1H, NH-20], [4.67 (d, J = 11.1 Hz); 4.26 (br s); 3.62-3.58 (m), 1H, **10**], [3.84-3.75 (m); 3.57-3.49 (m); 3.47-3.35 (m); 3.33-3.02 (m), 4H, **21, 25**], [2.36-2.29 (m); 2.16-2.08 (m); 1.94-1.89 (m), 1H, **11**], 1.89-0.59 (m, 28H, **13, 14, 15, 16, 17, 22, 23, 24, 26, 27, 28, 29, 30**). ^{13}C NMR (151 MHz, Acetone) δ [172.1, 171.3, 170.8, 170.2, 169.6-8, **18**], [144.1, 143.8, 143.4-4],

[140.9, 140.6, 140.3, 131.0, 130.5, 130.0, 128.9, 128.8, 128.7, 128.6, 128.5-1, 2, 3, 6], [94.0, 93.1-5], [68.4, 67.0, 62.9, 39.1-10], [47.1, 44.6, 44.4, 39.5, 39.3-21, 25], [38.6, 37.2, 36.8-11], [33.2, 32.44, 32.40, 32.3, 32.2, 31.6, 31.2, 31.0, 30.39, 30.35, 28.6, 28.2, 28.0, 27.9, 27.2, 27.03, 26.97, 26.74, 26.69, 26.5, 26.4, 23.4, 22.9, 21.0, 20.8-22, 23, 26, 27, 28, 29], [14.2, 14.08-24, 30]. FAB-HRMS (m/z): calcd. For

5 $C_{25}H_{39}IN_2O_2 + H$: 527.2135, found 527.2125.


fgka: 1H NMR (600 MHz, Acetone- d_6) δ [8.32 (s); 7.93-7.87 (m); 6.88 (s), 1H, NH-20], [7.93-7.87 (m); 7.53-7.49 (m); 7.31 (dd, $J = 7.7, 1.6$ Hz); 7.25-7.15 (m), 4H, aromatic], 3.36 (d, $J = 11.1$ Hz, 1H, 11), 3.33-3.05 (m, 3H, 21, 25), 2.83-2.73 (m, 1H, 12), 2.02-0.56 (m, 27H, 13, 14, 15, 16, 17, 22, 23, 24, 26, 27, 28, 29, 30). ^{13}C NMR (151 MHz, Acetone) δ [172.8, 172.3-8, 18], 144.3 (4), [140.4, 131.1, 129.4, 126.9-1, 2, 3, 6], 93.1 (5), 69.5 (11), 62.2 (25), 39.4 (21), 37.0 (12), [32.70, 32.69, 32.53, 32.46, 32.2, 31.9, 31.6, 31.5, 31.43, 31.38, 30.3, 27.04, 26.99, 26.9, 26.81, 26.77, 26.7, 26.6, 26.5, 26.2, 25.5, 21.0, 20.8-13, 14, 15, 16, 17, 22, 23, 26, 27, 28, 29, 30], 14.1 (24). FAB-HRMS (m/z): calcd. For $C_{25}H_{37}IN_2O_2 + H$: 525.1978, found 525.1971.



fgla: 1H NMR (600 MHz, Acetone- d_6) δ [8.02-7.82 (m); 7.59-7.08 (m); 6.79-6.73 (m), 9H, aromatic], [7.59-7.08 (m); 7.02 (br s), 1H, NH-21], [4.87-4.52 (m); 3.69-3.65 (m), 1H, 12], [4.07-3.92 (m); 3.80-3.71 (m); 3.64-3.55 (m); 3.42-3.15 (m); 3.15-2.94 (m); 2.78-2.57 (m), 4H, 11, 26], 3.42-3.15 (m, 2H, 22), [2.38-2.06 (m); 2.05-0.76 (m), 17H, 14, 15, 16, 17, 18, 23, 24, 25]. ^{13}C NMR (151 MHz, Acetone- d_6) δ [172.1, 169.6-8, 19], [143.9, 143.7, 140.6, 140.4, 140.3, 139.7, 139.6-4, 27], [131.2, 131.1, 130.7, 129.81, 129.77, 129.3, 129.2, 129.0, 128.84, 128.81, 128.79, 128.5, 127.2, 126.9, 126.8-1, 2, 3, 6, 28, 29, 30, 31, 32], 93.8 (5), [67.0, 62.4-12], [49.0, 46.4-11, 26], 39.3 (22), 39.1 (13), [38.6, 37.3, 37.0, 36.9, 36.4, 34.8, 34.5, 33.0, 32.4, 32.3, 32.2, 31.02, 30.95, 30.40, 30.38, 30.35, 27.2, 27.00, 26.96, 26.67, 26.65, 26.4, 26.3,

21.0, 20.8-14, 15, 16, 17, 18, 23, 24], 14.1 (25). FAB-HRMS (m/z): calcd. For $C_{27}H_{35}IN_2O_2 + H$: 547.1822, found 547.1815.


fgma: 1H NMR (600 MHz, Acetone- d_6) δ [8.07-7.02 (m); 7.02-6.93 (m); 6.80-6.62 (m), 1H, NH- 20], [8.07-7.02 (m); 7.02-6.93 (m); 6.80-6.62 (m); 6.57-6.39 (m), 14H, aromatic], 4.65-4.60 (m, 1H, 26), [4.33-4.26 (m); 4.14 (br d); 3.63 (d, $J = 10.2$ Hz); 3.53 (d, $J = 10.3$ Hz), 1H, 11], 4.11-3.87 (m, 2H, 25), 3.35-3.01 (m, 2H, 21), 2.39-2.22 (m, 1H, 12), 2.03-0.42 (m, 17H, 13, 14, 15, 16, 17, 22, 23, 24). ^{13}C NMR (151 MHz, Acetone) δ [172.8, 172.7, 170.7, 170.3-8, 18], [143.6, 143.5, 143.42, 143.37, 142.9, 142.8-4, 27, 28], [141.2, 140.3, 139.8, 131.3, 131.0, 130.9, 130.0, 129.9, 129.7, 129.6, 129.51, 129.45, 129.4, 129.34, 129.27, 129.24, 129.16, 129.11, 129.07, 128.96, 128.91, 128.82, 128.75, 128.5, 127.5, 127.40, 127.37, 127.2, 126.9-1, 2, 3, 6, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38], [93.9, 92.7-5], 69 (11), [56.4, 55.7-25], [50.5, 50.4, 50.1-26], [39.6, 39.5-21], [38.3, 37.2-12], [32.9, 32.43, 32.40, 32.1, 31.3, 31.2, 30.9, 30.4, 27.04, 26.97, 26.6, 26.5, 26.3, 26.2, 20.9, 20.8 - 13, 14, 15, 16, 17, 22, 23], 14.1 (24). FAB-HRMS (m/z): calcd. For $C_{33}H_{39}IN_2O_2 + H$: 623.2135, found 623.2127.



fgna: 1H NMR (600 MHz, Acetone- d_6) δ [8.63 (br s); 8.14-6.76 (m), 1H, NH-20], 8.14-6.76 (m, 4H, aromatic), 3.63-3.48 (m, 1H, 10), 3.32-3.11 (m, 2H, 21), 2.71-2.60 (m, 1H, 11), 2.20-0.52 (m, 26H, 12, 13, 14, 15, 16, 22, 23, 24, 26, 27, 28). ^{13}C NMR (151 MHz, Acetone) δ [173.3, 173.2, 168.9, 166.4-8, 18], 146.6 (4), [142.2, 141.1, 140.3, 133.9, 132.0, 131.1, 131.0, 129.10, 128.98, 128.6, 127.7-1, 2, 3, 6], [96.8, 96.7 - 5], 72.5 (10), 50.3 (25), [39.45, 39.33, 39.29 - 21], 37.1 (11), [30.9, 14.3, 13.8-26, 27, 28], [32.6, 32.5, 32.4, 31.7, 31.1, 30.3, 28.6, 27.2, 27.0, 26.9, 26.8, 26.7, 26.6, 26.5, 26.4, 25.7, 20.9, 20.8, 20.7-12, 13, 14, 15, 16, 22, 23], [14.5, 14.1-24]. FAB-HRMS (m/z): calcd. For $C_{23}H_{35}IN_2O_2 + H$: 499.1822, found 499.1816.


fgoa: 1H NMR (600 MHz, Acetone- d_6) δ [8.33 (br s); 7.98-7.90 (m); 7.35-7.29 (m); 7.23-7.15 (m), 1H, NH-20], [7.98-7.90 (m); 7.58-7.49 (m); 7.35-7.29 (m); 7.23-7.15 (m), 4H, aromatic], 3.80-3.65 (m, 1H, 25), 3.35-3.22 (m, 1H, 10), [3.35-3.22 (m); 3.22-3.08 (m), 2H, 21], 2.82-2.75 (m, 1H, 11), 2.03-0.55 (m,

23H, 13, 14, 15, 16, 17, 22, 23, 24, 26, 27). ^{13}C NMR (151 MHz, Acetone) δ [172.6, 172.5-8, 18], [144.3-4], [140.5, 131.2, 129.4, 126.9-1, 2, 3, 6], 93.2 (5), 68.3 (10), 53.5 (25), 39.4 (21), 36.9 (11), [32.7, 32.51, 32.48, 32.4, 32.2, 31.51, 31.46, 31.4, 30.4, 28.6, 27.2, 27.0, 26.9, 26.81, 26.79, 26.72, 26.68, 26.63, 26.58, 26.5, 26.4, 25.7, 21.8, 21.5, 21.0, 20.9, 20.82, 20.78, 20.7, 20.5, 20.1, 14.5-13, 14, 15, 16, 17, 22, 23], [21.8, 20.5-26, 27], 14.1 (24). FAB-HRMS (m/z): calcd. For $\text{C}_{22}\text{H}_{33}\text{IN}_2\text{O}_2 + \text{H}$: 485.1665, found 485.1658.



fgpa: ^1H NMR (600 MHz, Acetone- d_6) δ [7.94-7.82 (m); 7.52-7.38 (m); 7.33-7.10 (m), 4H, aromatic], [7.56 (br s); 7.38-7.09 (m); 6.94 (m), 1H, NH-20], [4.68 (d, $J = 11.1$ Hz); 4.26 (br s), 1H, 10], [3.91-3.78 (m); 3.64-3.55 (m); 3.52-3.39 (m); 3.34-3.13 (m); 3.13-3.06 (m), 2H, 25], 3.34-3.13 (m, 2H, 21), [2.32 (d, $J = 12.0$ Hz); 2.13-2.08 (m), 1H, 11], 2.00-0.53 (m, 26H, 13, 14, 15, 16, 17, 22, 23, 24, 26, 27, 28, 29). ^{13}C NMR (151 MHz, Acetone) δ [172.3, 171.0, 170.9, 170.2, 169.7-8, 18], 143.9 (4), [141.0, 140.7, 140.4, 131.1, 130.6, 129.1, 129.0, 128.9, 128.8-1, 2, 3, 6], 93.2 (5), 62.9 (10), [45.7, 43.1-25], [39.6, 39.4-21], 36.9 (11), 36.6 (27), [39.3, 38.6, 37.6, 37.3, 37.2, 37.0, 33.3, 32.6, 32.4, 32.3, 31.3, 31.2, 31.1, 30.52, 30.47, 27.9, 27.3, 27.2, 27.1, 26.9, 26.81, 26.76, 26.6, 26.5, 23.23, 23.19, 23.1, 23.0, 21.1, 21.0-13, 14, 15, 16, 17, 22, 23, 26], [22.7, 22.42, 22.37, 22.3-28, 29], 14.2 (24). FAB-HRMS (m/z): calcd. For $\text{C}_{24}\text{H}_{37}\text{IN}_2\text{O}_2 + \text{H}$: 512.1900, found 513.1973.


fgqa: ^1H NMR (600 MHz, Acetone- d_6) δ [7.72-7.66 (m); 7.47-6.56 (m), 9H, aromatic], 7.47-6.56 (m, 1H, NH-20), [4.70 (br s); 4.44-4.40 (m), 1H, 11], 3.34-3.12 (m, 2H, 21), [2.24-2.15 (m); 1.80-0.77 (m), 17H, 13, 14, 15, 16, 17, 22, 23, 24], 2.04-1.93 (m, 1H, 12). ^{13}C NMR (151 MHz, Acetone) δ [178.4, 171.5-8, 18], [143.9, 94.2-4, 5, 25], [139.9, 130.5, 130.4, 130.0, 129.5, 129.2, 128.5, 128.2-1, 2, 3, 6, 26, 27, 28, 29, 30], 60.5 (11), 39.5 (21), 37.1 (12), [32.5, 32.4, 31.1, 30.7, 30.4, 30.3, 27.1, 26.5, 26.4, 26.3, 26.2, 20.8-13, 14, 15, 16, 17, 22, 23], 14.1 (24). FAB-HRMS (m/z): calcd. For $\text{C}_{25}\text{H}_{31}\text{IN}_2\text{O}_2 + \text{H}$: 519.1509, found 519.1523.



figra: ^1H NMR (600 MHz, Acetone- d_6) δ [8.30 (br s); 8.10-7.05 (m), 1H, NH-**20**], 8.10-7.05 (m, 9H, aromatic), [5.73-5.58 (m); 5.03-4.79 (m), 1H, **25**], [3.90-3.71 (m); 3.51-3.09 (m), 1H, **10**], [3.51-3.09 (m); 2.98-2.91 (m), 2H, **21**], 2.72-2.56 (m, 1H, 11), 2.01-0.56 (m, 20H, **13**, **14**, **15**, **16**, **17**, **22**, **23**, **24**, **26**).

5 ¹³C NMR (151 MHz, Acetone) δ [172.9, 172.7, 170.8-8, 18], [142.9, 139.0-4, 27], [141.4, 140.9, 139.8, 131.8, 131.5, 131.1, 130.4, 129.8, 129.7, 129.5, 129.33, 129.29, 129.2, 129.1, 128.9, 128.8, 128.62, 128.55, 128.4, 128.1, 127.8-1, 2, 3, 6, 28, 29, 30, 31, 32], 94.4 (5), [69.3, 68.5-10], [60.0, 59.6-25], [39.5, 39.3 - 21], 36.8 (11), [32.6, 32.5, 32.3, 31.9, 31.41, 31.36, 31.3, 30.5, 27.04, 26.96, 26.85, 26.8, 26.7, 26.5, 26.4, 26.2, 20.96, 20.93, 20.8, 19.4, 19.1-13, 14, 15, 16, 17, 22, 23], 17.6 (26), 14.1 (24). FAB-
10 HRMS (*m/z*): calcd. For C₂₇H₃₅IN₂O₂ + H: 547.1822, found 547.1825.

fgta: ^1H NMR (600 MHz, Acetone- d_6) δ [7.71 (d, $J = 7.9$ Hz); 7.49-7.37 (m); 7.23-7.18 (m); 6.94-6.91 (m), 8H, aromatic], [7.49-7.37 (m); 7.37-7.31 (m), 1H, NH-**20**], [4.81 (br s); 4.58 (d, $J = 11.0$ Hz), 1H, **10**], [3.30-3.24 (m); 3.20-3.13 (m), 2H, **21**], [2.16-2.08 (m); 1.98-1.93 (m); 1.78-1.59 (m); 1.17-1.04 (m), 10H, **13**, **14**, **15**, **16**, **17**], 1.92-1.84 (m, 1H, **11**), 1.59-1.51 (m, 2H, **22**), 1.44-1.36 (m, 2H, **23**), 0.92 (t, $J = 7.4$ Hz, 3H, **24**). ^{13}C NMR (151 MHz, Acetone) δ [171.2, 170.9-8, **18**], [143.7, 133.7, 115.3, 94.1-4, **5**, **25**, **28**], [140.01, 140.00, 132.4, 130.7, 129.5, 129.1, 128.3-1, **2**, **3**, **6**, **26**, **27**, **29**, **30**], 67.0 (**10**), 39.6 (**21**), 37.2 (**11**), [32.4, 31.0, 30.5, 30.3, 27.0, 26.4, 26.3, 20.8-**13**, **14**, **15**, **16**, **17**, **22**, **23**], 14.1 (**24**). FAB-HRMS (m/z): calcd. For $\text{C}_{55}\text{H}_{30}\text{ClIN}_5\text{O}_2 + \text{H}$: 553.1119, found 553.1120.




fgua: ^1H NMR (600 MHz, Acetone- d_6) δ [7.72-7.67 (m); 7.61-7.56 (m); 7.44-7.39 (m); 7.35-7.30 (m); 7.21-7.15 (m); 7.06 (br s); 6.98-6.85 (m); 6.75-6.67 (m), 8H, aromatic], [7.44-7.39 (m); 7.35-7.30 (m), 1H, NH-20], [4.71 (br s); 4.45 (d, $J = 11.1$ Hz), 1H, 10], 3.69 (s, 3H, 32), 3.32-3.14 (m, 2H, 21), [2.28-2.08 (m); 1.99-0.57 (m), 18H, 11, 13, 14, 15, 16, 17, 22, 23, 24]. ^{13}C NMR (151 MHz, Acetone) δ [171.7, 159.7-8, 18], [144.2, 133.7, 115.5, 94.1-4, 5, 25, 28], [139.9, 131.6, 130.6, 129.4, 128.2, 121.6, 115.3, 114.7, 114.2-1, 2, 3, 6, 26, 27, 29, 30], 67.7 (10), 55.6 (32), 39.6 (21), [39.2, 37.1, 32.5, 31.1, 30.6, 30.4, 27.1, 26.5, 26.3, 26.2, 20.8-13, 14, 15, 16, 17, 22, 23], 37.0 (11), 14.1 (24). FAB-HRMS (m/z): calcd. For $\text{C}_{26}\text{H}_{33}\text{I}\text{N}_2\text{O}_3 + \text{H}$: 549.1614, found 549.1624.

fgva ^1H NMR (600 MHz, Acetone- d_6) δ [7.86 – 6.90 (m); 6.59 – 6.47 (m), 9H, 1, 2, 3, 6, NH-21, 25, 26, 28, 29], [4.78 (br s); 4.55 (d, $J = 10.9$ Hz), 1H, 11], 3.33 – 3.08 (m, 2H, 21), [2.12 (s); 2.00 – 0.81 (m), 17H, 13, 14, 15, 16, 17, 22, 23, 24].

^{13}C NMR (151 MHz, Acetone- d_6) δ 171.1 (7, 18), 143.7 (4, 10), [140.0, 139.1, 138.3, 132.8, 130.7, 129.5, 128.3 – 1, 2, 3, 6, 25, 26, 28, 29], 116.5 (27), [94.1, 93.5 – 5], 43.1 (11), [39.6, 39.3 – 21], 37.2 (12), [32.43, 32.39, 31.0, 30.6, 30.4, 27.0, 26.4, 26.3, 26.1, 20.8 – 13, 14, 15, 16, 17, 22, 23] 14.1 (24).

FAB-HRMS (m/z): calcd. For $\text{C}_{25}\text{H}_{30}\text{I}_2\text{N}_2\text{O}_2 + \text{H}$: 645.0475, found 645.0476.



fgwa ^1H NMR (600 MHz, Acetone- d_6) δ 8.18 – 6.47 (m, 9H, 1, 2, 3, 6, NH-20, 25, 26, 28, 29), [4.85 (br s, 1H); 4.63 (d, J = 11.0 Hz); 3.89 (s); 3.83 – 3.78 (m); 3.72 – 3.67 (m), 1H, 11], 3.32 – 3.12 (m, 2H, 21), [2.16 – 2.07 (m); 2.00 – 0.81 (m), 13, 14, 15, 16, 17, 22, 23, 24].


^{13}C NMR (151 MHz, Acetone- d_6) δ [172.1, 171.0 – 7, 18], [143.5, 141.9 – 4, 10, 27], 140.1, 131.4, 130.9, 129.6, 128.4, 127.1, 126.1, 113.3, 113.0 – 1, 2, 3, 6, 25, 26, 28, 29], 125.9 (31), [67.0, 63.9, 52.7, 52.0 – 11], [39.6, 39.4, 39.3 – 21], [43.2, 42.0, 37.4, 37.3 – 12], 41.6, 40.7, 37.3, 32.5, 32.4, 31.0, 30.7, 30.6, 30.5, 30.3, 27.0, 26.9, 26.44, 26.39, 26.35, 26.2, 26.1, 20.8, 20.7, 20.6 – 13, 14, 15, 16, 17, 22, 23], [14.1, 14.0 – 24].

FAB-HRMS (m/z): calcd. For $\text{C}_{26}\text{H}_{30}\text{F}_3\text{IN}_2\text{O}_2 + \text{H}$: 587.1382, found 587.1381.

fgxa ^1H NMR (600 MHz, Acetone- d_6) δ [7.75 – 6.90 (m); 6.66 – 6.48 (m), 9H, 1, 2, 3, 6, NH-20, 25, 26, 28, 29], [4.80 (br s); 4.62 – 4.48 (m); 3.66 – 3.52 (m), 1H, 11], 3.30 – 3.13 (m, 2H, 21), [2.18 – 2.07 (m); 1.98 – 0.80 (m), 17H, 13, 14, 15, 16, 17, 22, 23, 24].

^{13}C NMR (151 MHz, Acetone- d_6) δ [177.0, 171.0, 167.0 – 7, 18], [143.7, 121.8 – 4, 10], [140.0, 133.0, 132.7, 132.3, 132.2, 130.7, 129.5, 128.3 – 1, 2, 3, 6, 25, 26, 28, 29], 115.8 (27), 94.0 (5), 43.1 (11), [39.6, 39.3 – 21], [37.2, 37.2 – 12], [32.4, 32.4, 31.0, 30.8, 30.7, 30.5, 30.4, 27.1, 27.04, 26.98, 26.5, 26.42, 26.39, 26.3, 26.1, 20.8, 20.7, 20.6 – 13, 14, 15, 16, 17, 22, 23], [14.1, 14.03, 13.99 – 24].

FAB-HRMS (m/z): calcd. For $\text{C}_{25}\text{H}_{30}\text{BrIN}_2\text{O}_2 + \text{H}$: 597.0614, found 599.0597.



MO-02 ^1H NMR (600 MHz, Acetone- d_6) δ 7.90 – 6.79 (m, 13H, 1, 2, 5, 6, NH-20, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35), 6.62 (br d, J = 7.7 Hz, 2H, 1, 2, 5, 6, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35), 4.73 – 4.40 (m, 1H, 11), 3.34 – 3.11 (m, 2H, 21), [2.34 – 2.07 (m); 2.01 – 0.76 (m), 17H, 13, 14, 15, 16, 17, 22, 23, 24].


^{13}C NMR (151 MHz, Acetone- d_6) δ [172.5, 169.5 – 7, 18], [141.1, 139.2, 137.7, 135.0, 131.0, 129.7, 127.7 – 3, 4, 10, 30], [130.4, 130.2, 130.1, 130.0, 129.8, 129.6, 129.33, 129.25, 129.1, 128.9, 128.6, 128.3, 128.3, 128.2, 127.9, 127.4 – 1, 2, 5, 6, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35], 49.5 (11), [39.5, 39.4, 39.3 – 21], [37.2, 37.1 – 12], [32.4, 30.9, 30.8, 30.7, 30.6, 30.4, 27.13, 27.07, 26.41, 26.38, 26.3, 26.1, 20.8, 20.7 – 13, 14, 15, 16, 17, 22, 23], [14.1, 14.0 – 24].

FAB-HRMS (m/z): calcd. For $\text{C}_{31}\text{H}_{36}\text{N}_2\text{O}_2 + \text{H}$: 469.2855, found 469.2853.

MO-03 ^1H NMR (600 MHz, Acetone- d_6) δ 8.33 – 8.21 (m, 1H, NH-20), 7.90 – 7.00 (m, 9H, 1, 2, 5, 6, 33, 34, 35, 36, 37), 3.78 – 3.48 (m, 1H, 21), [3.37 – 3.30 (m); 3.26 (tt, J = 12.0, 3.6 Hz); 3.11 – 3.04 (m), 1H, 10], [3.14 (d, J = 11.1 Hz); 3.11 – 3.04 (m), 1H, 11], 2.75 – 2.50 (m, 1H, 12), 1.99 – 0.24 (m, 30H, 13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31).

^{13}C NMR (151 MHz, Acetone- d_6) δ [173.5, 173.1, 171.8, 171.1 – 7, 18], [141.2, 141.0, 139.8, 138.8, 138.3, 138.0 – 3, 32], [130.8, 130.7, 130.1, 129.9, 129.7, 129.5, 129.4, 129.2, 128.6, 128.4, 127.2, 126.9, 126.7 – 1, 2, 5, 6, 33, 34, 35, 36, 37], [70.0, 69.4 – 11], [61.9, 61.2 – 10], [48.7, 48.0 – 21], [37.2, 37.0, 36.9 – 12], [33.6, 33.4, 33.2, 33.0, 32.3, 31.8, 31.64, 31.56, 31.5, 31.3, 31.2, 31.1, 30.6, 30.4, 27.12, 27.06, 27.04, 26.96, 26.9, 26.8, 26.7, 26.6, 26.48, 26.46, 26.4, 26.30, 26.26, 25.9, 25.6, 25.5, 25.3, 25.2, 25.1, 23.3, 14.4 – 13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31].



FAB-HRMS (m/z): calcd. For $\text{C}_{33}\text{H}_{44}\text{N}_2\text{O}_2 + \text{H}$: 501.3481, found 501.3483.



MO-04 ^1H NMR (600 MHz, Acetone- d_6) δ [8.60 (br s); 8.35 – 8.19 (m), 1H, NH-20], 7.78 – 6.83 (m, 13H, 1, 2, 5, 6, 33, 34, 36, 37, 40, 41, 42, 43, 44), 3.80 – 3.43 (m, 1H, 21), [3.40 – 3.27 (m); 3.21 (tt, J = 11.9, 3.6 Hz); 3.18 – 3.06 (m), 1H, 10], 3.18 – 3.06 (m, 1H, 11), 2.77 – 2.64 (m, 1H, 12), 1.98 – 0.40 (m, 30H, 13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31).

^{13}C NMR (151 MHz, Acetone) δ [173.6, 173.2, 171.8, 171.0 – 7, 18], [158.20, 158.18, 157.9, 157.7 – 35, 39], [138.9, 138.4, 138.1, 138.0, 136.1, 136.0 – 3, 4, 32], [131.7, 131.3, 130.9, 130.8, 130.7, 130.5, 130.0, 129.8, 129.5, 128.5, 128.4, 127.3, 126.9, 124.6, 124.5, 121.9, 120.0, 119.9, 119.4, 119.3, 118.0, 117.1 – 1, 2, 5, 6, 33, 34, 36, 37, 40, 41, 42, 43, 44], [70.0, 69.3 – 11], [61.9, 61.2 – 10], [48.8, 48.0 – 21], [37.3, 37.1, 37.0 – 12], [33.6, 33.4, 33.1, 31.84, 31.76, 31.7, 31.54, 31.51, 31.3, 31.2, 30.6, 30.4, 27.12, 27.06, 27.0, 26.9, 26.84, 26.77, 26.7, 26.6, 26.5, 26.4, 26.4, 26.29, 26.27, 26.2, 25.9, 25.6, 25.5, 25.3, 25.2, 25.1 – 13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31].

FAB-HRMS (m/z): calcd. For $\text{C}_{39}\text{H}_{48}\text{N}_2\text{O}_3 + \text{H}$: 593.3743, found 593.3751.




rgka ^1H NMR (600 MHz, Acetone- d_6) δ 8.55 (s, 1H, 16), 7.53 – 7.45 (m, 3H, 1, 2, 4), 7.45 – 7.39 (m, 2H, 3, 6), 3.54 – 3.46 (m, 1H, 24), 3.37 (d, J = 11.0 Hz, 1H, 10), 3.34 – 3.09 (m, 2H, 19), 2.70 (m, J = 14.3, 12.9 Hz, 1H, 11), 1.92 – 1.53 (m, 13H), 1.53 – 1.46 (m, 2H, 21), 1.43 – 1.35 (m, 2H, 22), 1.34 – 0.95 (m, 6H), 0.94 (t, J = 7.3 Hz, 3H, 23).

5 ^{13}C NMR (151 MHz, Acetone) δ 173.88 (7), 173.06 (7), 138.73 (12), 130.46 (5), 129.47 (1, 2, 4), 126.91 (3, 6), 69.57 (10), 61.99 (24), 39.15 (19), 36.80 (11), 32.39, 31.84, 31.49, 31.38, 30.23, 30.10, 29.97, 29.84, 29.71, 29.58, 29.45, 27.13, 27.07, 26.80, 26.76, 26.61, 26.30, 25.65 (21), 20.74 (22), 20.62, 14.02 (23), 13.98.

10 rgoa ^1H NMR (600 MHz, Acetone- d_6) δ 8.56 (s, 1H, 17), 7.52 – 7.39 (m, 5H, 1, 2, 3, 4, 6), 3.98 (m, 1H, 10), 3.37 – 3.27 (m, 2H, 13, 18), 3.18 – 3.08 (m, 1H, 18), 2.75 – 2.67 (m, 1H, 14), 1.91 – 1.64 (m, 6H, 20, 21, 22, 23, 24), 1.54 – 1.45 (m, 2H, 19), 1.44 – 1.35 (m, 2H, 25), 1.29 – 1.19 (m, 6H, 11, 12, 20, 21, 22, 23, 24), 1.09 (d, J = 6.8 Hz, 3H, 11, 12), 1.05 – 0.97 (m, 1H, 20, 21, 22, 23, 24), 0.94 (t, J = 7.3 Hz, 3H, 26).

15 ^{13}C NMR (151 MHz, Acetone) δ 173.72 (7, 15), 173.17 (7, 15), 138.72 (5), 130.43 (1, 2, 3, 4, 6), 129.50 (1, 2, 3, 4, 6), 126.97 (1, 2, 3, 4, 6), 68.34 (13), 53.33 (10), 39.12 (18), 36.70 (14), 32.37 (19), 31.42 (20, 24), 31.34 (20, 24), 27.05 (21, 22, 23), 26.79 (21, 22, 23), 26.76 (21, 22, 23), 21.44 (11, 12), 20.75 (11, 12, 25), 20.72 (11, 12, 25), 14.01 (26).

rgkc:



20

[rgkc]


Yield: 140.9 mg (0.33 mmol, 66%)

25 ^1H NMR (600 MHz, Chloroform- d) δ [8.72 (d, J = 5.2 Hz) NH major; 8.54 (d, J = 5.2 Hz) NH minor, 1H], 7.49 – 7.35 (m, 5H) aromatic, [3.81 (m) 12 major; 3.72 (m) 12 minor, 1H], [3.58 (tt, J = 12.0, 3.2 Hz) 19 minor; 3.48 (tt, J = 12.0, 3.2 Hz) 19 major, 1H], [3.38 (d, J = 10.9 Hz) 9 major; 3.19 (d, J = 10.9 Hz) 9 minor, 1H], [2.76 (qt, J = 11.4, 3.2 Hz) 20 major; 2.46 (qt, J = 11.4, 3.2 Hz) 20 minor, 1H], 1.99 – 0.85 (m, 30H) 13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31.

30 ^{13}C NMR (151 MHz, Chloroform- d) δ [173.36, 172.26 (7, 10)], 137.39 (4), 129.77 (1), 128.66 (3, 5), 126.02 (2, 6), 69.18 (9), 61.48 (19), 47.31 (12), 35.69 (20), [32.80, 32.59, 31.59, 31.22, 30.99, 30.51,

26.35, 25.96, 25.93, 25.83, 25.67, 25.49, 24.79, 24.47, 24.40 (13, 14, 15, 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)].

5 rgna:




[rgna]

Yield: 96.2 mg (0.26 mmol, 52%)

10 ^1H NMR (600 MHz, Chloroform-*d*) δ 9.11 (s, 1H) NH, [8.08 – 7.50 (m) aromatic minor; 7.50 – 7.35 (m) aromatic major, 5H], [6.00 (s) 19 minor; 3.25 (q, J = 6.5 Hz) 19 major, 2H], [5.30 (d, J = 4.3 Hz) 10 minor; 3.56 (d, J = 9.8 Hz) 10 major, 1H], [2.51 (q, J = 11 Hz) 13 major; 2.16 (s) 13 minor, 1H], 1.95 – 0.88 (m, 26H) 14, 15, 16, 20, 21, 22, 23, 24, 25, 26, 27.

15 ^{13}C NMR (151 MHz, Chloroform-*d*) δ [175.15, 174.18, 169.44, 165.69 (7, 12)], [141.28, 133.91 (4)], [130.48, 130.06, 129.79, 129.03, 128.58, 127.86 (1, 2, 3, 5, 6)], [78.63, 72.30 (10)], [59.88, 59.77 (11)], [40.49, 35.95 (13)], 39.28 (19), [31.96, 31.79, 31.72, 30.94, 29.78 (14, 15, 16)], [31.50, 27.60, 26.60, 26.40, 26.37, 26.32, 26.29, 20.51, 20.34 (20, 21, 23, 24, 25, 26, 27)] [14.13, 14.03 (22)].

20 qgkc:




[qgkc]

Yield: 110.0 mg (0.24 mmol, 48%)

25 ^1H NMR (600 MHz, Chloroform-*d*) δ [8.58 (d, J = 7.1 Hz) NH minor; 8.48 (dd, J = 7.1 Hz) NH major, 1H], 7.37 – 6.87 (m, 4H) aromatic, [3.97 (s) 14 minor; 3.90 (s) 14 minor; 3.79 (d, J = 3.5 Hz) 14 major, 12 major, 4H], [3.82 (d, J = 3.5 Hz) 12 major, 14 major; 3.71 (m) 12 minor, 1H], [3.56 (t, J = 11.9 Hz) 16 minor; 3.26 (m) 16 major; 2.44 (t, J = 10.9 Hz) 16 minor, 1H], [3.35 (d, J = 11.1 Hz) 9 minor; 3.31 (d, J = 11.2 Hz) 9 major; 3.17 (d, J = 10.9 Hz) 9 minor, 1H], [2.83 (m) 17 major; 2.62 (m) 17 minor, 1H], 2.19 – 0.66 (m, 30H) 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33.

¹³C NMR (151 MHz, Chloroform-*d*) δ [172.39, 172.15, 171.11, 170.92 (7, 10)], [155.30, 154.62 (3)], [130.26, 130.00, 127.39, 125.80, 121.13, 120.86, 111.02, 110.80 (1, 2, 5, 6)], [127.36, 127.26 (4)], [69.20, 68.91 (9)], [61.58, 61.16 (16)], [55.37, 55.27 (14)], 47.26 (12), [36.03, 35.97 (17)], [32.91, 32.67, 32.62, 32.60, 31.57, 31.54, 31.09, 31.06, 31.00, 30.67, 30.60, 30.46, 26.49, 26.40, 26.08, 26.04, 26.01, 25.95, 25.88, 25.81, 25.76, 25.72, 25.66, 25.57, 24.89, 24.86, 24.52, 24.41 (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)].

ngkc:




[ngkc]

Yield: 157.9 mg (0.34 mmol, 69%)

¹H NMR (600 MHz, Chloroform-*d*) δ [8.35 (s) NH major; 8.30 (s) NH minor, 1H], 7.42 (m, 1H) 2, 7.32 (m, 2H) (1, 6), [7.20 (m) 5 major; 7.10 (m) 5 minor, 1H], 3.77 (m, 1H) 17, [3.41 (d, *J* = 11.1 Hz) 11 minor; 3.35 (d, *J* = 11.1 Hz) 11 major, 1H], 3.19 (m, 1H) 12, 2.81 (m, 1H) 14, 2.18 – 0.80 (m, 30H) 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32.

¹³C NMR (151 MHz, Chloroform-*d*) δ [171.90, 170.33 (8, 13)], 137.35 (3), 130.91 (4), [130.33, 130.29 (1)], [130.24, 130.19 (2)], [127.59, 127.40 (6)], [127.11, 126.32 (5)], 69.35 (11), [62.14, 61.81 (12)], [48.05, 47.72 (17)], [36.73, 36.23 (14)], [33.40, 33.15, 33.11, 32.94, 31.90, 31.72, 31.42, 31.27, 31.21, 30.94, 30.88, 26.70, 26.66, 26.31, 26.25, 26.17, 26.15, 26.10, 26.02, 25.97, 25.93, 25.81, 25.08, 24.99, 24.92 (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)].

ogkc:




[ogkc]

Yield: 182.5 mg (0.36 mmol, 72%)

¹H NMR (600 MHz, Chloroform-*d*) δ [8.37 (s) NH major; 8.30 (s) NH minor, 1H], 7.60 (ddd J = 8.1, 4.1, 1.1 Hz, 1H) 2, 7.35 (td, J = 7.5, 1.1 Hz, 1H) 6, 7.25 (td, J = 7.8, 1.7 Hz, 1H) 1, [7.18 (dd, J = 7.6, 1.7 Hz) 5 major; 7.07 (dd, J = 7.6, 1.7 Hz) 5 minor, 1H], 3.77 (m, 1H) 17, [3.41 (d, J = 11.2 Hz) 11 minor; 3.34 (d, J = 11.0 Hz) 11 major, 1 Hz], [3.24 (m) 12 minor; 3.17 (tt, J = 11.7, 3.6 Hz) 12 major, 1H], [2.88 (m) 14 minor; 2.80 (qt, J = 11.5, 3.3 Hz) 14 major, 1H], 2.29 – 0.78 (m, 30H) 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32.

¹³C NMR (151 MHz, Chloroform-*d*) δ [171.79, 171.02 (8, 13)], [139.64, 139.46 (4)], [133.43, 133.41 (2)], [130.46, 130.37 (1)], [128.06, 127.92 (6)], [126.99, 126.48 (5)], 119.80 (3), 69.33 (11), 61.82 (12), [48.18, 47.73 (17)], [36.81, 36.19 (14)], [33.45, 33.29, 33.20, 32.95, 31.97, 31.75, 31.64, 31.43, 30.95, 30.85, 26.69, 26.66, 26.31, 26.26, 26.14, 26.12, 25.99, 25.92, 25.80, 25.09, 25.06, 24.97 (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)].

fhka:




[fhka]

Yield: 131.0 mg (0.27 mmol, 53%)

¹H NMR (600 MHz, Chloroform-*d*) δ [8.37 (s) NH major; 8.11 (s) NH minor, 1H], 7.85 (dd, J = 8.0 Hz, 1H) 2, 7.38 (td, J = 7.5, 1.1 Hz, 1H) 6, 7.13 (dd, J = 7.6, 1.6 Hz, 1H) 5, 7.09 (td, J = 7.7, 1.6 Hz, 1H) 1, 3.44 (d, J = 11.3 Hz, 1H) 10, 3.32 (m, 1H) 13, 3.30 – 3.18 (m, 2H) 16, 3.14 (tt, J = 11.8, 3.7 Hz, 1H) 11, 1.99 – 0.78 (m, 25H) 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29.

¹³C NMR (151 MHz, Chloroform-*d*) δ [173.27, 172.53 (7, 12)], 143.52 (4), 139.83 (2), 130.49 (1), 128.58 (6), 125.98 (5), 92.93 (3), 68.47 (10), 61.82 (11), 39.48 (16), 39.41 (13), [32.12, 32.10, 31.48, 31.20, 30.62, 26.11, 25.78, 25.52, 25.21, 25.06, 20.67, 14.18 (17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29)].

fhkc:




[fhkc]

Yield: 179.6 mg (0.33 mmol, 67%)

¹H NMR (600 MHz, Chloroform-*d*) δ [8.36 (d, J = 7.8 Hz) NH major; 8.12 (s) NH minor, 1H], 7.85 (dd, J = 8.0, 1.1 Hz, 1H) 2, 7.38 (td, J = 7.5, 1.1 Hz, 1H) 6, [7.12 (dd, J = 7.6, 1.6 Hz) 5 major; 7.02 (d, J = 7.5 Hz) 5 minor, 1H], 7.09 (m, 1H) 1, 3.78 (m, 1H) 16, [3.47 (s) 10 minor; 3.41 (d, J = 11.2 Hz) 10 major, 1H], 3.31 (m, 1H) 13, 3.13 (tt, J = 11.8, 3.7 Hz, 1H) 11, 1.98 – 0.80 (m, 28H) 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31.

¹³C NMR (151 MHz, Chloroform-*d*) δ [172.52, 172.26 (7, 10)], 143.64 (4), [139.91, 139.81 (2)], [130.46, 130.32 (1)], 128.56 (6), 126.08 (5), 93.12 (3), 68.65 (10), 61.79 (11), 48.36 (16), 39.32 (13), [33.59, 33.21, 32.13, 31.52, 31.10, 30.49, 26.13, 26.00, 25.78, 25.54, 25.26, 25.14, 25.07, 25.00 (17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31)].

[tgka]:



[tgka]


Yield: 138.6 mg (0.35 mmol, 71%)

¹H NMR (600 MHz, Chloroform-*d*) δ 8.53 (s, 1H) NH, 3.60 (tt, J = 11.9, 3.6 Hz) 6, [3.26 (m, 1H) 11; 3.09 (m, 1H) 11], 3.19 (d, J = 10.6 Hz, 1H) 5, 2.63 (q, J = 11.7, 11.1 Hz, 1H) 8, [2.42 (d, J = 14.0 Hz, 1H) 1; 2.16 (d, J = 14.0 Hz, 1H) 1], 1.87 – 0.66 (m, 36H) 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28.

^{13}C NMR (151 MHz, Chloroform-*d*) δ [173.64, 173.35 (2, 7)], 69.15 (5), 59.85 (6), 46.41 (1), 38.73 (11), 35.96 (8), 31.63 (22), 30.16 (23, 24, 25), [31.57, 31.49, 31.44, 31.24, 30.85, 30.65, 30.16, 26.37, 26.14, 25.96, 25.93, 24.96, 20.16, 20.02 (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27)], 13.71 (28).

5

tgkc:



[tgkc]

Yield: 154.5 mg (0.37 mmol, 74%)

10


^1H NMR (600 MHz, Chloroform-*d*) δ 8.55 (d, J = 8.2 Hz, 1H) NH, 3.69 (m, 1H) 11, 3.60 (tt, J = 12.0, 3.6 Hz, 1H) 6, 3.16 (d, J = 10.8 Hz, 1H) 5, 2.66 (q, J = 11.6 Hz, 1H) 8, [2.44 (d, J = 13.7 Hz, 1H) 1; 2.13 (d, J = 13.9 Hz, 1H) 1, 1.87 – 0.66 (m, 39H) 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30.

15

^{13}C NMR (151 MHz, Chloroform-*d*) δ [173.94, 172.78 (2, 7)], 69.63 (5), 60.25 (6), 47.65 (11), 46.72 (1), 36.24 (8), [33.12, 33.06, 31.58, 31.22, 30.90, 26.72, 26.48, 26.34, 26.29, 26.25, 25.96, 25.29, 24.90, 24.81 (12, 13, 14, 15, 16, 17, 18, 19, 20, 21)], 31.78 (22), 30.54 (23, 34, 25).

20

ugkc:



[ugkc]

Yield: 171.9 mg (0.39 mmol, 78%)

25


^1H NMR (600 MHz, Chloroform-*d*) δ 8.37 (d, J = 64.8 Hz, 1H) NH, [7.85 (dd, J = 8.0, 1.2 Hz) 2 minor; 7.39 (dq, J = 8.8, 4.6, 3.9, 1.8 Hz) 2 major, 1H], 7.21 (m, 2H) 5, 6, 7.11 (m, 1H) 1, [3.78 (m) 12 major;

3.68 (m) 12 minor, 1H], [3.55 (m) 15 minor; 3.31 (tt, $J = 11.8, 3.9$ Hz) 15 major; 2.44 (t, $J = 11.8$ Hz) 15 minor, 1H], [3.36 (d, $J = 21.2$ Hz) 9 major, 3.15 (m) 9 minor, 1H], [2.78 (m) 16 major; 2.63 (m) 16 minor, 1H], 2.27 – 0.66 (m, 30H) 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32.

5 ^{13}C NMR (151 MHz, Chloroform-*d*) δ [172.21, 168.74 (7, 10)], [139.89, 131.29, 130.46, 128.63, 126.78, 126.18, 124.95, 116.32 (1, 2, 5, 6)], 69.57 (9), 62.07 (15), 47.75 (12), [36.32, 36.23 (16)], [33.23, 32.93, 32.23, 31.86, 31.36, 31.11, 30.90, 30.82, 30.03, 26.74, 26.69, 26.29, 26.27, 26.20, 26.15, 26.13, 26.09, 25.98, 25.35, 25.31, 25.10, 24.77 (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32).

10 ^{19}F NMR (565 MHz, Chloroform-*d*) δ [114.35, 116.86 (13)]

vgkc:




15 [vgkc]
Yield: 131.0 mg (0.27 mmol, 53%)

^1H NMR (600 MHz, Chloroform-*d*) δ [8.52 (s) 11 minor; 8.27 (d, $J = 8.1$ Hz) 11 major; 8.05 (s) 11 minor, 1H], [7.74 (d, $J = 7.8$ Hz) 2 major; 7.72 (d, $J = 7.9$ Hz) 2 minor, 1H], 7.60 (t, $J = 7.5$ Hz, 1H) 6, 7.54 (t, $J = 7.7$ Hz, 1H) 1, 7.33 (d, $J = 7.5$ Hz) 5 major; 7.17 (d, $J = 7.6$ Hz) 5 minor, 1H], 3.84 – 3.64 (m, 1H) 12, [3.56 (m) 15 minor; 3.12 (tt, $J = 11.4, 3.8$ Hz) 15 major; 2.45 (m) 15 minor, 1H], [3.42 (d, $J = 11.7$ Hz) 9 minor; 3.35 (d, $J = 11.1$ Hz) 9 major; 3.17 (d, $J = 11.4$ Hz) 9 minor, 1H], [2.85 (d, $J = 11.5$ Hz) 14 minor; 2.77 (qt, $J = 11.5, 3.3$ Hz, 1H) 14 major; 2.62 (m) 14 minor, 1H], 2.02 – 0.63 (m, 30H) 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31.

25 ^{13}C NMR (151 MHz, Chloroform-*d*) δ [171.67, 170.67 (7, 10)], 136.10 (4), [132.31, 129.83, 127.47, 136.31 (1, 2, 5, 6)], 124.96 (3), 123.15 (32), [69.37, 61.84, 48.28, 36.18 (9, 12, 14, 15)], 33.16, 32.54, 31.48, 31.09, 30.84, 30.80, 26.75, 26.65, 26.34, 26.32, 26.28, 26.04, 25.99, 25.79, 25.10 (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31).

30 ^{19}F NMR (565 MHz, Chloroform-*d*) δ 59.17 (33, 34, 35)


faqa:



[faqa]

¹H NMR (600 MHz, Chloroform-*d*) δ [Missing NH peak], [7.71 – 6.77 (m, 9H) (1, 2, 3, 6, 23, 24, 25, 26, 27)], 4.46 (d, J = 12.1 Hz, 1H) 9, 3.35 (q, J = 6.9 Hz, 2H) 17, 2.46 (s, 1H) 13, 1.63 – 0.84 (m, 13H) 14, 15, 18, 19, 20.

10 **faaAa:**




[faaAa]

¹H NMR (600 MHz, Chloroform-*d*) δ [Missing an aromatic peak], [7.73 – 6.75 (m, 10H) 1, 2, 3, 6, 23, 24, 27, 29], 4.46 (d, J = 10.9 Hz, 1H) 9, 3.35 (q, J = 6.5 Hz, 2H) 17, 2.46 (s, 1H) 13, 1.61 – 1.53 (m, 2H) 18, 1.40 (m, 2H) 19, 1.09 (d, J = 6.5 Hz, 3H) 14 or 15, 1.01 (d, J = 6.6 Hz, 3H) 14 or 15, 0.93 (t, J = 7.4 Hz, 3H) 20.

20 **Example 3: Additional Synthetic Procedures.**


tert-butyl (2-cyclohexyl-2-(2-iodo-*N*-(prop-2-yn-1-yl)benzamido)acetyl)(naphthalen-2-yl)carbamate (EM67):



A two-necked flask was charged with **fgbd** (100 mg, 0.18 mmol) in dry DCM (2 mL) under nitrogen atmosphere. To this was added triethylamine (25.4 μL , 0.18 mmol), DMAP (22 mg, 0.18 mmol), and Boc_2O (119 mg, 0.55 mmol). The reaction mixture was stirred for 7 h at 25°C . An additional 3 equivalents of Boc_2O (119 mg, 0.55 mmol) were added to the flask. The reaction was stopped after 21 h. Volatiles were then removed *in vacuo* and the crude product was purified using a silica plug with 3:1 hexanes/EtOAc. Yield 118 mg (99%, 0.18 mmol), yellow oil.


ESI(+)-LRMS (m/z): Calcd for $\text{C}_{33}\text{H}_{35}\text{IN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 651.16, found 651.56, 673.28 $[\text{M}+\text{Na}]^+$.

2-cyclohexyl-2-(2-iodo-N-(prop-2-yn-1-yl)benzamido)acetic acid (EM68a):




EM67 (7.5 mg, 0.012 mmol) was dissolved in THF- H_2O (4:1, 1 mL). $\text{LiOH}\cdot\text{H}_2\text{O}$ (1.8 mg, 0.042 mmol) was added and the mixture was stirred at room temperature. After 3 d the reaction was complete by TLC (3:1 hexanes/EtOAc and 5:1 DCM/MeOH) and the reaction was quenched with 1 M HCl (1 mL). The product was extracted 3x with DCM (0.5 mL), dried over Na_2SO_4 , and the solvent removed *in vacuo*. Crude yield 6.5 mg (0.015 mmol, excess mass). Product was not purified.

2-cyclohexyl-2-(2-iodo-N-(prop-2-yn-1-yl)benzamido)acetic acid (EM75):



EM67 (118 mg, 0.18 mmol) was dissolved in THF- H_2O (4:1, 10 mL). $\text{LiOH}\cdot\text{H}_2\text{O}$ (23 mg, 0.54 mmol) and H_2O_2 (30% w/v, 98 μL , 0.98 mmol) were added and the mixture was stirred at room temperature. After 3 h the reaction was complete by TLC (3:1 hexanes/EtOAc and 5:1 DCM/MeOH) and

the reaction was quenched with 1 M HCl (3 mL). The product was extracted 3x with DCM (2 mL), dried over Na₂SO₄, and the solvent removed *in vacuo*. Yield: 39 mg (51%, 0.092 mmol), yellow solid.



¹H NMR (600 MHz, Methanol-*d*₄) δ 7.98-7.88 (m, 1H, 7), 7.53-7.16 (m, 3H, 1, 2, 4), [4.88-4.77 (m); 3.75-3.66 (m), 1H, 11], [4.68-4.35 (m); 4.17-4.02 (m); 3.81 (d, *J* = 18.6 Hz), 2H, 12], 2.72-2.58 (m, 1H, 20), 2.29-0.85 (m, 11H, 13, 16, 17, 21, 22, 23) ppm. ESI(+)-LRMS (*m/z*): Calcd for C₁₈H₂₀INO₅ [M+H]⁺ 426.05, found 426.87.

Example 4: Chemical Synthesis

As demonstrated herein, the compounds of the invention inhibit bacterial GlcNAcases. For example, compound **BL.fgba** inhibits the GlcNAcase LytG, and has concentration-dependent bacteriostatic activity in the bacterial strain *B. subtilis*. This compound has exhibited a minimum inhibitory concentration (MIC) of 63 μM in whole cell assays.


In order to identify a more potent GlcNAcase inhibitor, analogs of **BL.fgba** were prepared. Specifically, seven compounds were synthesized, each involving a small modification to the **BL.fgba** structure: five with alternate substituents off of the benzoic acid moiety, and two with alternate substituents off of the aldehyde. The sugar and triazole linker were kept constant across all compounds.

In addition to a second-generation library of compounds, alternate routes to obtain the dipeptide Ugi-derived compounds were explored. In particular, synthetic routes that allow for the modification of the isocyanide substituent beyond the limited number of isocyanides commercially available were explored. A new route to introduce varied functionality at the C-terminus of the dipeptide was thus investigated.


As described herein, a library of GlcNAc triazoles (GNT's) as well as dipeptides without a sugar moiety were tested in whole-cell conditions against *B. subtilis* using a resazurin microtiter assay. These data were used both to evaluate the relative inhibitory capabilities of the compounds as well as determine MIC values *in vivo*.

Ugi Synthesis


Terminal alkynes were prepared using the Ugi four-component condensation reaction. The Ugi condensation is a one-pot reaction that combines an acid, an amine, an aldehyde, and an isocyanide to form a dipeptide. The general Ugi reaction utilized is shown in Scheme 2. In certain non-limiting embodiments, propargylamine and n-butyl isocyanide were held constant for all Ugi-derived compounds. The first four Ugi compounds synthesized held all aspects of the **fgba** structure (Scheme 3) constant while varying the substituent on the benzyl ring of the acid. The last two Ugi compounds instead varied only the aldehyde substituent while retaining the iodobenzoic acid. The synthetic schemes and final structures of non-limiting Ugi compounds are illustrated in Scheme 4.



Scheme 2. General Ugi reaction using propargyl amine and n-butyl isocyanide.




Scheme 3. fgba.




Scheme 4. Synthesis of Ugi compounds; varied substituents highlighted in red.

As a non-limiting procedure, first, the aldehyde and propargylamine were reacted for 30 minutes at elevated temperature to form the imine intermediate. The n-butyl isocyanide was then added, followed by the benzoic acid after another 20 minutes. All reagents were used in a 1:1 ratio. The reaction was run to completion according to TLC. Products were analyzed with ^1H - and COSY NMR. Generally, products were pure enough to be used directly in the click reaction with the GlcNAc-azide. In certain embodiments, an acid/base extraction was used to purify the compound.


The compounds depicted in Schemes 5-6 were also prepared using the Ugi reaction.




fgca (87%)




fgia (64%)




fgja (92%)




fgka (78%)




fgla (89%)




fgma (80%)




fgna (23%)




fgoa (46%)




fgpa (71%)




fgqa (81%)




fgra (72%)



fgsa (90% crude)




fgta (76%)



fgua (69%)


Scheme 5.



Scheme 6.


GNT Synthesis

Terminal alkyne Ugi products were then coupled to 1-azido-N-acetylglucosamine (1) using the click reaction. The general scheme for the click process is shown in Scheme 7.




Scheme 7. General synthesis of GNT products.

The redox couple of Cu(0) powder and Cu(II) sulfate was used to catalyze the azide-alkyne coupling. The terminal alkyne was used in excess to ensure that all of the azide was consumed. Unreacted alkyne could then be easily removed using a silica plug following the reaction. Thus, no column chromatography was necessary for purification. Copper was removed from the reaction mixture prior to silica plug purification using commercially available copper chelating resin. The synthetic schemes and final structures are shown in Schemes 8-9.



Scheme 8. Synthesis of GNT compounds; varied substituent highlighted in red.




Scheme 9. Synthesis of GNT compounds; varied substituent highlighted in red.

Peptide hydrolysis route


- 5 An alternate method to achieve variable terminal amide moieties was pursued. Instead of constructing the dipeptide backbone stepwise, the Ugi reaction was used. Once the product was isolated, the N-terminal secondary amide was selectively hydrolyzed to yield an acid. The acid was then converted to an amine of choice through peptide coupling or left as an acid or ester. It should be noted that removal the C-terminal amide moiety after the Ugi reaction is complete is done in the presence of a second amide.
- 10 A number of “convertible isocyanides” such as Gilley’s indole-isocyanide or Pirrung’s ortho-substituted phenylisocyanides allow for the ready removal of the secondary amide using mild conditions, though these isocyanides are synthesized themselves through multi-step processes. Using exclusively commercially available starting materials and reagents, the acid derivative of **fgba** (**EM68**) was successfully synthesized.
- 15 Two **fgba** derivatives, **fgbd** and **fgkd**, were synthesized through the Ugi reaction utilizing 2-naphthylisocyanide in place of n-butylisocyanide as illustrated in Scheme 12. 2-Naphthylisocyanide proved to be poorly soluble in the methanol solvent because of the large nonpolar aromatic structure. Both products were purified via column chromatography to remove starting material remaining after incomplete reaction. Without wishing to be limited by any theory, the highly conjugated ring system of
- 20 2-naphthylisocyanide may improve the capability of the amine to act as a leaving group during hydrolysis, through stabilization of the intermediate charge on the nitrogen. Under basic conditions, a negative

charge may be transiently formed on the nitrogen as it leaves, but this should be delocalized by resonance throughout the large conjugated aromatic system.



Scheme 12. Ugi reaction synthesis of *fgbd* and *fgkd*

fgbd was subjected to acidic hydrolysis conditions (1:1 3 N HCl/THF, 50 °C, 24 h). Using ESI-MS, masses correlating to a mixture of single and double hydrolysis products were observed, with little apparent specificity for cleavage of one peptide bond over the other. Selective cleavage was attempted by first adding tert-butyloxycarbonyl to the secondary amide followed by basic hydrolysis conditions as shown in Scheme 13. Basic hydrolysis was performed using lithium hydroxide, both with and without hydrogen peroxide. Both conditions were successful, though the reaction proceeded to completion in 3 hours with addition of H₂O₂ and required 3 days without it. No hydrolysis of the 2-iodobenzoic acid substituent was observed and the reaction went cleanly to completion. This facile and selective modification of the C-terminal amide moiety provides access to a wide range of substituents, either through esterification of the acid group or amide couplings, and circumvents the need for convertible isocyanides.



Scheme 13. Synthesis of *fgba* acid derivative

Procedure for Suzuki Coupling to make MO2, MO3, MO4

A mixture of an iodide Ugi substrate (1 equiv), a boronic acid (1.5 equiv), a degassed 2 M aqueous solution of Na₂CO₃ (3 equiv) and Pd(PPh₃)₄ (2 mol%) in equal parts toluene and water was heated at 100°C in a sealed vial in the microwave for 10 h. The reaction progress was monitored by TLC
5 by inserting a capillary tube through a vent needle. The reaction mixture was cooled to room temperature and extracted with saturated brine solution, dried with NaSO₄, and concentrated in vacuo. Finally, the residue was subjected to flash SiO₂ column chromatography (eluent: EtOAc/hexanes) to yield the product in approximately 70% yield.

10 Example 5: Resazurin *in vivo* Assay

Selected compounds of the invention were assayed for antibiotic activity. The initial screens were performed against whole cells, and not purified enzymes, in order to eliminate those compounds that did not reduce bacterial growth

Compounds were tested *in vivo* for their capacity to inhibit *B. subtilis* growth. In order to
15 determine growth inhibition, a resazurin whole-cell assay was used (Kuhn, *et al.*, 2014, Medchemcomm 5:1213–1217). Briefly, second-passage bacteria were incubated with inhibitor in a 96-well plate for four hours, then resazurin dye was added and color/ fluorescence change was observed. The resazurin is naturally a blue color, but with reductive species produced during bacterial growth, it is reduced to resorufin, which appears pink. Resorufin is also fluorescent and can be measured by a plate-reader.

20 **BL.ngba, BL.logba, BL.pgba, BL.qgba, BL.fhba, BL.fiba** showed no significant growth inhibition at 125 μM. Tested compounds are exemplified in Scheme 14. In an initial set-up, each compound was evaluated at the single concentration of 250 μM in triplicate. Growth controls containing no inhibitory compound, sterility controls without inoculation, and controls containing a known antibiotic, chloramphenicol, were also included. After incubation of the bacteria with the inhibitors for four hours,
25 resazurin dye was added and the plate was immediately placed in a plate reader. Fluorescence of each well was measured at 590 nm at 0, 5, 10, 20, and 60 min after addition of the dye. A higher growth rate of bacteria produces more resorufin and thus more fluorescence. Lower fluorescence therefore indicates better growth inhibition.

Several compounds exhibited significant antibacterial activity. At a single concentration of
30 inhibitor, it was also possible to qualify the relative inhibitory activity by comparing the fluorescence between any two wells. At 250 μM, a wide range of fluorescence values were observed after 60 minutes as opposed to an “on or off” fluorescence reading for each compound. This indicates that the more active inhibitors measurably reduced fluorescence more efficiently than less active inhibitors, even when

evaluated at one concentration. In certain embodiments, it may be possible to identify potent inhibitors exclusively by single-concentration fluorescence analysis.

Fluorescence was further evaluated as it developed over time. After 60 minutes of incubation with dye, all the fluorescence values continued to increase even at the end-point time, without signs of saturation. Without wishing to be limited by any theory, while 60 minutes was enough time to observe resolution of the compounds' inhibitory efficacy, additional incubation time may yield even further resolution especially at low fluorescence values. Due to the constantly increasing fluorescence, the gain of the plate reader had to be lowered for each consecutive reading. Thus, in order to compare fluorescence values over time, the factor by which the measured fluorescence was greater than the background fluorescence of only the dye at each individual time point is reported. The graphs of the fluorescence over time and at 60 minutes are given in Figs. 3-4, respectively. A reproduction of the plate is illustrated in Fig. 6B, with selected compounds outlined in red. Table 1 illustrates the identity of each of the plate wells, and Table 2 illustrates the fluorescence values for each well at 60 minutes. Fig. 5 illustrates fluorescence values at 60 minutes.

Table 1. Minimum inhibitory concentration (MIC) of several diamide compounds against Gram-positive organisms.

Compound	<i>S. aureus</i> (µg/mL)	<i>P. difficile</i> (µg/mL)	<i>S. pneumoniae</i> (µg/mL)	<i>B. subtilis</i> (µg/mL)
fgba	2.81	-	-	-
fgqa	3.64	-	-	-
fgbb	-	-	3.62	-
fgbc	-	-	3.56	-
fgna	-	17.52	-	-
fgka	-	-	-	11.53
fgkc	-	-	-	1.65

Table 2. Fluorescence values of single concentration whole-cell resazurin assay at 60 min.

	1	2	3	4	5	6	7	8	9	10	11	12
A	2011	2032	2051	2155	2132	2059	1915	2075	1984	2054	2088	1917
B	2716	3515	3496	28448	38753	34884	45887	9817	11125	47182	45775	46536
C	11306	15248	12800	31913	30770	31261	22293	24175	22048	50422	46868	43091
D	15175	14377	16691	30662	40093	34125	39903	23346	5343	44287	43008	42008
E	5587	7956	7645	3131	3444	14226	14499	15876	44514	1	1	0
F	12796	12614	19796	41889	41174	40181	10879	11581	11336	1	1	1
G	28543	27527	41369	33670	36362	41358	3143	3462	4326	2291	1912	2277
H	35447	38746	38556	3209	3029	3516	4835	6373	6493	2206	2288	2166


Compounds fgkc, fgkb, rgba, fgka, fgoa, and fgna exhibited the highest degree of inhibition as shown by the smallest values of fluorescence.

5 fgkc, fgkb, rgba, fgoa, fgka and fgna - *B. subtilis* Lyt G.


fgkc, fgbb, and fgbc - *S. pneumoniae*.

fgna - *C. difficile*.


fgba or fgqa - *S. aureus*.




fbqb




fgka




fgna




fgqb




fgba




fgoa




fgbb




fgpa




fgkb




rgba



fgqa



fgkc



Scheme 14. GNT and Ugi-derived compounds used in resazurin microtiter assay.

In one aspect, as for the inclusion of aromatic substituents aside from the benzoyl moiety. **fbqb**,
 5 compound with aromatic groups on all substituents of the dipeptide exhibited lower activity. **fgla**, **fgma**,
fgra, and **fgta** also contained large aromatic amine substituents and exhibited poor activity compared to
 aliphatic derivatives. As single aromatic groups were sequentially replaced by aliphatic groups (primarily

cyclohexyl), the efficacy of the resulting compounds uniformly increased. The trend was illustrated in the sequence: **fbqb**, **fgqb**, **fgqc/fgkb**, **fgka/fgkc**. Within this overall trend, modification of the amine component appeared to have a more substantial effect on efficacy, compared to modification of the isocyanide component. In addition, the specific aliphatic groups utilized both for the isocyanide and amine moieties had significant impact. Inclusion of cyclohexyl groups generally appeared to exhibit the greatest improvement, while longer and less branched aliphatic groups were less effective. This was illustrated in the sequence: **fgba**, **fgpa**, **fgna/fgoa**, **fgka**. In particular, a secondary carbon immediately adjacent to the nitrogen of the amine component appears to be advantageous. While the sugar moiety may contribute to the specificity of the inhibitor, its presence decreases efficacy in comparison to the dipeptide alone. This was illustrated in the disparity between **Bl.rgba** and **rgba**.

In order to verify our results, the 250 μ M single-concentration resazurin assay was repeated twice more. The cumulative results are plotted in Fig. 5. Though some deviation was observed among runs, the results were within the predicted range of error. The four most potent inhibitors **fgkc**, **fgka**, **fgoa**, and **rgba** demonstrated the highest degree of inhibitory activity across all three runs.

Using the four most potent inhibitors **fgkc**, **fgka**, **fgoa**, and **rgba**, a serial dilution resazurin assay was performed in which each inhibitor was sequentially diluted across a 96-well plate beginning at 250 μ M and halving in concentration down to 7.9 μ M. Each dilution was run in triplicate. Each well contained a total of 100 μ L of liquid, including DMSO with dissolved compound, LB broth, and 40 μ L of cells (a 1:20 dilution). Growth controls containing no inhibitory compound, sterility controls without inoculation, and controls containing a known antibiotic, chloramphenicol, were also included. At this point, plates were incubated at 37 °C for 4 hours under aerobic conditions, but due to experimental error plates were only incubated for 30 minutes. After incubation, resazurin solution was added to each well and plates were incubated. A change in color from blue to pink indicated reduction of resazurin, and therefore bacterial growth. Minimum inhibitory concentration (MIC) was determined as the lowest drug concentration that prevented the color change from blue to pink. The fluorescence was again quantified by a plate reader, and two identical plates were run simultaneously. Images of the resulting well plates along with a table indicating the layout of the plates are shown in Fig. 6. Even without a quantitative analysis, it is very clear from the color change from blue to pink at which concentration each compound became too dilute. **rgba** exhibited an MIC of 250 μ M. **fgoa** inhibited bacterial growth down to a concentration of 62.5 μ M. **fgkc** and **fgka** inhibited growth down to the lowest concentration of 7.9 μ M.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.


Although the invention has been disclosed and described with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in

the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

CLAIMS

What is claimed:

1. A compound of formula I, or a salt or solvate thereof:



R₁ is selected from the group consisting of aryl and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₂ is selected from the group consisting of C₁-C₈ alkyl, C₃-C₈ cycloalkyl, allyl, propargyl, homopropargyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, wherein the alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₃ is selected from the group consisting of C₃-C₈ cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl, aryl or heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl);

R₄ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₈ cycloalkyl, arylalkyl and heteroarylalkyl, wherein the alkyl, cycloalkyl, arylalkyl or heteroarylalkyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl); and

R₅ is H or methyl.

2. The compound of claim 1, wherein in R₁ has at least one substituent ortho to the carbonyl group *a* selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, NO₂, -C(=O)H, -C(=O)OH, -C(=O)O(C₁-C₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁-C₆ alkyl), and -C(=O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl).

3. The compound of claim 2, wherein at least one substituent ortho to the carbonyl group α is selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br and I.

4. The compound of claim 1, wherein R₁ is selected from the group consisting of phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl and p-methoxyphenyl.


5. The compound of claim 1, wherein R₂ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, heteroaryl, aryl-(CH₂)₁₋₂-, and heteroaryl-(CH₂)₁₋₂-, wherein the alkyl, cycloalkyl, phenyl, heteroaryl, aryl-(CH₂)₁₋₂-, or heteroaryl-(CH₂)₁₋₂-group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, I, and NO₂.

6. The compound of claim 5, wherein R₂ is selected from the group consisting of C₁-C₆ alkyl, C₅-C₆ cycloalkyl, allyl, propargyl, homopropargyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, p-methoxyphenyl, benzyl, Ph(CH₂)₂-, Ph₂CHCH₂-, and Ph(CH₃)CH-.


7. The compound of claim 1, wherein R₃ is selected from the group consisting of C₅-C₆ cycloalkyl, phenyl, o-iodophenyl, o-bromophenyl, o-chlorophenyl, o-fluorophenyl, o-methoxyphenyl, p-iodophenyl, p-bromophenyl, p-chlorophenyl, p-fluorophenyl, and p-methoxyphenyl.

8. The compound of claim 1, wherein R₄ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, benzyl, and phenyl-(CH₂)₂-, wherein the alkyl, cycloalkyl, phenyl or benzyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₆ alkyl, OH, O(C₁-C₆ alkyl), F, Cl, Br, and I.


9. The compound of claim 1, which is selected from the group consisting of:




fgca




fgia




fgja




fgbd




fgkd




rgba




ogba




pgba




qgba




flba




fiba




fbqb




fgka




fgna




fgqb




fgba




fgoa




fgbb




fgpa




fgkb




fgqa




fgqc




fgra




fgbc




fgla




fgta




fgkc




fgma




fgua




fgsa




fgva




fgwa




fgxa




MO2




MO3




MO4




rgkc (66%)




rgna (52%)




pgkc (48%)




rgka




rgoa




qgkc




ngkc (69%)




ogkc (72%)




fhka (65%)




fhkc (67%)




tgka (71%)




tgkc (74%)




ugkc (78%)




vgkc (53%)




faqa




faaAa




fhqa





fhaAa



fgqd



MJ02



and

5

10. The compound of claim 9, which is selected from the group consisting of **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka**, **fgna**, **fgbb**, **fgqa** and **fgbc**.

11. The compound of claim 10, wherein the compound is **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** or **fgna**.

12. The compound of claim 10, wherein the compound is **fgkc**, **fgbb**, or **fgbc**.

13. The compound of claim 10, wherein the compound is **fgba** or **fgqa**.

14. The compound of claim 10, wherein the compound is **fgna**.

15. The compound of claim 1, wherein the salt of compound I is an acid addition salt and is selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic,

lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid, and any combinations thereof.

16. The compound of claim 1, wherein the salt is a base addition salt and is selected from the group consisting of calcium, magnesium, potassium, sodium, ammonium, zinc, a basic amine salt, and any combinations thereof, wherein the basic amine is selected from the group consisting of triethylamine, diisopropylethylamine, trimethylamine, N,N'-dibenzylethylene-diamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and any combinations thereof.

17. A pharmaceutical composition comprising a compound of any one of claims 1-16 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, further comprising at least one additional antibacterial agent.

19. The pharmaceutical composition of claim 18, wherein the at least one additional antibacterial agent comprises at least one agent selected from the group consisting of amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim.

20. The pharmaceutical composition of claim 18, wherein the compound and the at least one antibacterial agent are co-formulated in the composition.

21. A method of inhibiting a N-acetylglucosaminidase in a cell, the method comprising contacting the cell with a compound of any one of claims 1-16.

22. A method of inhibiting a N-acetylglucosaminidase in the cytosol of a cell, the method comprising contacting the N-acetylglucosaminidase with any one of claims claim 1-16.

23. The method of claim 21 or claim 22, wherein the N-acetylglucosaminidase is

derived from a bacterium, a fungus or a cancer cell.

24. The method of claim 23, wherein the N-acetylglucosaminidase comprises an autolysin.

25. A method of treating or preventing a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-16, thereby treating or preventing a bacterial infection in a subject.

26. The method of any one of claims 21, 22 and 25, wherein the bacterium is Gram-positive.

27. The method of claim 26, wherein the Gram-positive bacterium is selected from the group consisting of *Streptococcus sp.*, *Staphylococcus sp.*, *Enterococcus sp.*, *Corynebacterium sp.*, *Listeria sp.*, *Clostridium sp.* and *Bacillus sp.*

28. The method of claim 27, wherein the Gram-positive bacterium is *Clostridium difficile*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, vancomycin intermediate resistance *S. aureus* (VISA), *Enterococcus faecalis*, vancomycin resistant enterococci (VRE), *Streptococcus pyogenes*, *Bacillus anthracis*, *Corynebacterium diphtheria* or *Bacillus cereus*.

29. The method of any one of claims 21, 22 and 25, wherein the bacterium is Gram-negative.

30. The method of claim 29, wherein the Gram-negative bacterium is selected from the group consisting of *Salmonella sp.*, *Escherichia sp.*, *Klebsiella sp.*, *Acinetobacter sp.*, *Pseudomonas sp.*, *Vibrio sp.* and *Enterobacter sp.*

31. The method of claim 30, wherein the Gram-negative bacterium is *Salmonella enterica*, *Salmonella typhi*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* or *Pseudomonas aeruginosa*.

32. The method of claim 25, wherein the subject is further administered at least one additional antibacterial agent.

33. The method of claim 32, wherein the at least one antibacterial agent comprises at least one agent selected from the group consisting of amoxicillin, azithromycin, biacin, biocef, cefaclor, cinoxacin, ciprofloxacin, clindamycin, doryx, emgel, enoxacin, fortaz, gatifloxacin, levofloxacin, linezolid, maxaquin, moxifloxacin, neomycin, ofloxacin, penicillin, rifampin, sparfloxacin, streptomycin, sulfatrim, tetracycline, trovafloxacin, vancomycin and zotrim.

34. The method of claim 32, wherein the compound and the at least one antibacterial agent are co-administered to the subject.

35. The method of claim 34, wherein the compound and the agent are co-formulated.

36. The method of claim 25, wherein the compound is administered to the subject by at least one route selected from the group consisting of intravenous, oral, inhalational, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary and topical routes.

37. The method of claim 25, wherein the compound is **fgkc**, **fgkb**, **rgba**, **fgoa**, **fgka** or **fgna** and the bacteria is *B. subtilis* Lyt G.

38. The method of claim 25, wherein the compound is **fgkc**, **fgbb**, or **fgbc** and the bacteria is *S. pneumoniae*.

39. The method of claim 25 wherein , the compound is **fgba** or **fgqa** and the bacteria is *S. aureus*.

40. The method of claim 25, wherein, the compound is **fgna** and the bacteria is *C. difficile*.

41. The method of claim 25, wherein the subject is a mammal.

42. The method of claim 37, wherein the mammal is a human.



43. A prepackaged pharmaceutical composition comprising a compound of any one of claims 1-16, or a salt or solvate thereof and an instructional material for use thereof

44. The prepackaged pharmaceutical composition of claim 43, wherein the

instructional material comprises instructions for preventing or treating a bacterial infection in a subject.

45. The prepackaged pharmaceutical composition of claim 43, further comprising an applicator.

1/8



2/8

Growth Inhibition Resazurin Assay: Fluorescence Over Time




Fig. 3




Fig. 4




Fig. 5




Fig. 6A

6/8




Fig. 6B

7/8

Inhibitor	<i>B. subtilis</i> (μ M)	<i>S. aureus</i> (μ M)	<i>E. faecalis</i> (μ M)	<i>S. pneumonia</i> (μ M)
fgia	-	2.9-5.8	-	
fgba	90	-	-	-
rgba	7.9-15.7	-	-	<5.85
Bl.qgba	-	-	3.1-6.25	-
fgna	-	-	-	<5.85
fgqb	-	-	-	<5.85
fgka	22	-	-	-

Fig. 7




Fig. 8

8/8




Fig. 9




Fig. 10A




Fig. 10B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/36972

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 43/00 (2016.01)

CPC - C07D 471/04; C07D 403/12; A61K 31/496

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

CPC: C07D 471/04; C07D 403/12; A61K 31/496

IPC: A01N 43/00 (2016.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 514/217.07, 217.11 (See Search Words Below)Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PATBASE: Full-text = AU BE BR CA CH CN DE DK EP ES FI FR GB IN JP KR SE TH TW US WO
Google: Scholar/Patents: antiinfective diamide bacteria iodophenyl subtilis cyclohexyl s.aureus pneumoniae propargyl antibacterial
phenyl butylamide acetylglucosaminidase cell combination vancomycin kit amoxicillin bromophenyl phenyl

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KUHN et.al. Anti-bacterial glycosyl triazoles-Identification of an N-acetylglucosamine derivative with bacteriostatic activity against Bacillus in MedChem Communication, 2014 August, Vol 5, pp. 1213?1217. abstract.; pg 2; pg 4; pg7;	1-22; 25; 32-45
Y	US 2013/0331456 A1 (BASU et.al.) 12 December 2013 (12.12.2013) para [0048]; pg 16-17, Table 4	1-22; 25; 32-45
Y	US 2006/0040871 A1 (LEVEY et.al.) 23 February 2006 (23.02.2006) para [0016];[0017];[0020];[0030];[0039];[0040]; [0045];[0047];[0048];[0135]-[0136]	11; 12; 14; 18-20; 25; 32-45
Y	US 4,610,983 A1 (TAKAGAWA et.al.) 09 September 1986 (09.09.1986) Col 4, In 49-65; Col 14, In 1 -10, Table 1	15; 16

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 August 2016 (12.08.2016)

Date of mailing of the international search report

02 SEP 2016

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/36972

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 23; 24; 26-31
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.